

11-15-00

A

Attorney Docket No.: 4990.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Commissioner for Patents
Washington, DC 20231



Express Mail Label No.: EL285641609US
Date of Deposit: November 13, 2000

Sir:

This is a request for filing a **divisional** application under 37 C.F.R.

1.53(b) of

Applicant(s): Blinkovsky *et al.*

Title: Carboxypeptidases And Nucleic Acids Encoding Same

56 pages of specification 6 sheets of Formal Drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:


Basic Fee:	\$710.00
Total Claims: 20 - 20 = 0 x 18 =	\$0
Independent Claims: 2 - 3 = 0 x 80 =	\$0
Total Fee:	\$710.00

This application is a divisional of pending U.S. application serial no. **08/943,714** filed on **October 3, 1997**, which is a continuation-in-part of U.S. application serial no. **08/757,534** filed on **November 27, 1996**, now abandoned, U.S. application serial no. **08/749,521** filed on **October 4, 1996**, now abandoned, and **PCT/DK97/00230** filed **May 20, 1997**, which claims priority of Danish application serial no. **0585/96** filed **May 20, 1996**, which applications are fully incorporated herein by reference.

Please charge the required fee, estimated to be **\$710.00**, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 13, 2000



Robert L. Starnes, Reg. No.: 41,324
Novo Nordisk Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: November 13, 2000

Examiner: To Be Assigned

For: Carboxypeptidases And Nucleic Acids Encoding Same

VERIFIED STATEMENT UNDER 37 CFR 1.821(f)


Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issue thereon.

Respectfully submitted,



Date: November 13, 2000

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: November 13, 2000

Examiner: To Be Assigned

For: Carboxypeptidases And Nucleic Acids Encoding Same

**REQUEST TRANSFER OF COMPUTER READABLE
SEQUENCE LISTING FROM PARENT CASE**


Commissioner for Patents
Washington, DC 20231

Sir:

The computer-readable form in this application, is identical with that filed in Application Serial No. **08/949,714** filed **October 3, 1997**, in accordance with 37 CFR 1.821 (e), please use the first filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally filed specification of the instant application.

The Examiner is hereby to contact the undersigned if there are any questions concerning this response.

Respectfully submitted,



Date: November 13, 2000

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: November 12, 2000

Examiner: To Be Assigned

For: Carboxypeptidases and Nucleic Acids Encoding Same

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION

At page 1, amend lines 6-10 to read as follows:

--This application is a divisional of pending U.S. application serial no. 08/943,714 filed on October 3, 1997, which is a continuation-in-part of U.S. application serial no. 08/757,534 filed on November 27, 1996, now abandoned, U.S. application serial no. 08/749,521 filed on October 4, 1996, now abandoned, and PCT/DK97/00230 filed May 20, 1997, which claims priority of Danish application serial no. 0585/96 filed May 20, 1996, which applications are fully incorporated herein by reference.--

IN THE CLAIMS

Please cancel claims 1-29 without prejudice or disclaimer. Please add new claims 30-49 as follows:

30. An isolated nucleic acid sequence encoding a polypeptide having carboxypeptidase activity, selected from the group consisting of:

(a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 70% identity with amino acids 19 to 555 of SEQ ID NO. 2;

(b) a nucleic acid sequence having at least 70% homology with nucleotides 55 to 1662 of SEQ ID NO. 1;

(c) a nucleic acid sequence which hybridizes under medium stringency conditions with (i) nucleotides 55 to 1662 of SEQ ID NO. 1, (ii) a subsequence of (i) of at least 100 nucleotides, or (iii) a complementary strand of (i) or (ii), wherein medium stringency conditions are defined as prehybridization and hybridization a 42°C in 5X SSPE, 0.3% SDS, 200 mg/ml sheared and denatured salmon sperm DNA, and 35% formamide;

(d) a subsequence of (a), (b), or (c), wherein the subsequence encodes a polypeptide fragment which has carboxypeptidase activity; and

(e) a nucleic acid sequence encoding a polypeptide having carboxypeptidase activity with (i) an optimal activity in the range of about pH 4.0 to about pH 5.0 at 25°C; (ii) an optimal activity in the range of about 55°C to about 60°C at pH 4; (iii) a residual activity of at least about 65.5% after 30 minutes at pH 4.0 and 60°C; and (iv) an ability to hydrolyze X from N-CBZ-Ala-X wherein N-CBZ is N-carbobenzoxy and X is any amino acid.

31. The nucleic acid sequence of claim 30, which encodes a polypeptide having an amino acid sequence which has at least 70% identity with amino acids 19 to 555 of SEQ ID NO. 2.

32. The nucleic acid sequence of claim 30, which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO. 2.

33. The nucleic acid sequence of claim 30, which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO. 2, or a fragment thereof which has carboxypeptidase activity.

34. The nucleic acid sequence of claim 33, which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO. 2.

35. The nucleic acid sequence of claim 34, which encodes a polypeptide consisting of amino acids 19 to 555 of SEQ ID NO. 2.

36. The nucleic acid sequence of claim 30, which has at least 70% homology with the nucleic acid sequence of SEQ ID NO. 1.

37. The nucleic acid sequence of claim 30, which has the nucleic acid sequence of SEQ ID NO. 1.

38. The nucleic acid sequence of claim 30, wherein the nucleic acid sequence hybridizes under medium stringency conditions with (i) nucleotides 55 to 1662 of SEQ ID NO. 1, (ii) a subsequence of (i) of at least 100 nucleotides, or (iii) a complementary strand of (i) or (ii), wherein medium stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 mg/ml sheared and denatured salmon sperm DNA, and 35% formamide.

39. The nucleic acid sequence of claim 30, wherein the nucleic acid sequence hybridizes under high stringency conditions with (i) nucleotides 55 to 1662 of SEQ ID NO. 1, (ii) a subsequence of (i) of at least 100 nucleotides, or (iii) a complementary strand of (i) or (ii), wherein medium stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 mg/ml sheared and denatured salmon sperm DNA, and 50% formamide.

40. The nucleic acid sequence of claim 30, which encodes a polypeptide having carboxypeptidase activity with (i) an optimal activity in the range of about pH 4.0 to about pH 5.0 at 25°C; (ii) an optimal activity in the range of about 55°C to about 60°C at pH 4; (iii) a residual activity of at least about 65.5% after 30 minutes at pH

4.0 and 60°C; and (iv) an ability to hydrolyze X from N-CBZ-Ala-X wherein N-CBZ is N-carbobenzoxy and X is any amino acid.

41. The nucleic acid sequence of claim 30, which is contained in the plasmid pEJG12 which is contained in *E. coli*, NRRL B-21616.

42. A nucleic acid construct comprising the nucleic acid sequence of claim 30 operably linked to one or more control sequences which direct the production of the polypeptide in a suitable expression host.

43. A recombinant expression vector comprising the nucleic acid construct of claim 42.

44. A recombinant host cell comprising the nucleic acid construct of claim 42.

45. A method for producing a polypeptide having carboxypeptidase activity comprising (a) cultivating the host cell of claim 44 under conditions suitable for production of the polypeptide; and (b) recovering the polypeptide.

46. An isolated nucleic acid sequence encoding a polypeptide having carboxypeptidase activity with (i) an optimal activity in the range of about pH 4.0 to about pH 5.0 at 25°C; (ii) an optimal activity in the range of about 55°C to about 60°C at pH 4; (iii) a residual activity of at least about 65.5% after 30 minutes at pH 4.0 and 60°C; and (iv) an ability to hydrolyze X from N-CBZ-Ala-X wherein N-CBZ is N-carbobenzoxy and X is any amino acid.

47. The isolated nucleic acid sequence of claim 46, wherein X is selected from the group consisting of Ile, Glu, Lys, Arg, Asp, Asn, Phe, and Tyr.

48. The isolated nucleic acid sequence of claim 46, which is obtained from a strain of *Aspergillus* or a teleomorph thereof.


49. The isolated nucleic acid sequence of claim 48, which is obtained from a strain of *Aspergillus oryzae* or a teleomorph thereof.

REMARKS

The present application is a divisional of pending U.S. application serial no. 08/943,714 filed on October 3, 1997, which is a continuation-in-part of U.S. application serial no. 08/757,534 filed on November 27, 1996, now abandoned, U.S. application serial no. 08/749,521 filed on October 4, 1996, now abandoned, and PCT/DK97/00230 filed May 20, 1997, which claims priority of Danish application serial no. 0585/96 filed May 20, 1996, which applications are fully incorporated herein by reference. Claims 1-29 have been cancelled and new claims 30-49 added.

Date: November 13, 2000

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324
Novo Nordisk Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616-4880
(530) 757-8100

CARBOXYPEPTIDASES AND NUCLEIC ACIDS ENCODING SAME

Cross-Reference to Related Applications

This application is a continuation-in-part of pending U.S. application serial no. 08/726,880 filed on October 4, 1996, a continuation-in-part of pending U.S. application serial no. 08/757,534 filed on November 27, 1996, and a continuation-in-part of PCT/DK97/00230 filed May 20, 1997, which claims priority of Danish application serial no. 0585/96 filed May 20, 1996, which applications are fully incorporated herein by reference.

Background of the Invention

Field of the Invention

The present invention relates to polypeptides having carboxypeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to methods of obtaining protein hydrolysates useful as flavor improving agents.

Description of the Related Art

Various food products, *e.g.*, soups, sauces and seasonings, contain flavoring agents obtained by hydrolysis of proteinaceous materials. This hydrolysis is conventionally accomplished using strong hydrochloric acid, followed by neutralization with sodium hydroxide. However, such chemical hydrolysis leads to severe degradation of the amino acids obtained during the hydrolysis, and also to hazardous byproducts formed in the course of this chemical reaction. Increasing concern over the use of flavoring agents obtained by chemical hydrolysis has led to the development of enzymatic hydrolysis processes.

Enzymatic hydrolysis processes aim at obtaining a high degree of hydrolysis (DH), and this is usually attained using a complex of unspecific acting proteolytic enzymes (*i.e.*, unspecific acting endo- and exo-peptidases). For example, WO 94/25580 describes a method for hydrolyzing proteins by use of an unspecific acting enzyme preparation obtained from

Aspergillus oryzae. Specific acting proteolytic enzymes have not been used for this purpose because such enzymes only lead to an inadequate degree of hydrolysis.

Acid carboxypeptidases (EC 3.4.16) are serine exopeptidases which catalyze the removal of amino acids from the C-terminus of peptides, oligopeptides or proteins. These carboxypeptidases generally have a narrow substrate specificity, *i.e.*, they can cleave only few amino acids.

Acid carboxypeptidases of *Aspergillus oryzae* have been reported previously. For instance, Nakadai, Nasuno, and Iguchi, 1972, *Agricultural and Biological Chemistry* 36: 1343-1352, disclose a carboxypeptidase I with a molecular weight of 120 kDa (gel filtration) and optimal activity in the pH range 3.0 to 4.0. Nakadai, Nasuno, and Iguchi, 1972, *Agricultural and Biological Chemistry* 36: 1473-1480, disclose a carboxypeptidase II with a molecular weight of 105 kDa (gel filtration) and optimal activity at pH 3.0. Nakadai, Nasuno, and Iguchi, 1972, *Agricultural and Biological Chemistry* 36: 1481-1488, disclose a carboxypeptidase III with a molecular weight of 61 kDa (gel filtration) and a pH optimum of 3.0. Nakadai, Nasuno, and Iguchi, 1972, *Agricultural and Biological Chemistry* 37: 1237-1251, disclose a carboxypeptidase IV with a molecular weight of 43 kDa (gel filtration) and optimal activity at pH 3.0. Tekeuchi and Ichishima, 1986, *Agricultural and Biological Chemistry* 50: 633-638, disclose a carboxypeptidase O with a molecular weight of 73 kDa (SDS-PAGE). Tekeuchi, Ushijima, and Ichishima, 1982, *Current Microbiology* 7: 19-23, disclose a carboxypeptidase O-1 and a carboxypeptidase O-2 both with a molecular weight of 63 kDa (gel filtration) and optimal activity at a pH in the range of 3.7 to 4.0. Ichishima *et al.*, 1972, *Journal of Biochemistry* 72: 1045-1048, disclose a comparison of the enzymatic properties of several *Aspergillus* acid carboxypeptidases. Azarenkova *et al.*, 1976, *Biokhimiya* 41: 20-27, disclose the isolation of an acid carboxypeptidase from *Aspergillus oryzae* with a molecular weight of 37 kDa (SDS-PAGE) and a pH optimum of 4 to 5.

The production of protein hydrolysates with desirable organoleptic properties and high degrees of hydrolysis generally requires the use of a mixture of peptidase activities. It would be desirable to provide a single component peptidase enzyme which has activity useful for improving the organoleptic properties and degree of hydrolysis of protein hydrolysates used in food products either alone or in combination with other enzymes.

It is an object of the present invention to provide improved polypeptides having carboxypeptidase activity as well as methods of obtaining protein hydrolysates with desirable organoleptic qualities and high degrees of hydrolysis.

Summary of the Invention

The present invention relates to isolated polypeptides having carboxypeptidase activity selected from the group consisting of:

(a) a polypeptide having an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2;

(b) a polypeptide encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) its complementary strand, or (iii) a subsequence thereof;

(c) a polypeptide having (i) optimal activity in the range of about pH 3.0 to about pH 7.5 at 25°C; (ii) optimal activity in the range of about 55°C to about 60°C at pH 4; (iii) a residual activity of at least about 65.5% after 30 minutes at pH 4.0 and 60°C; and (iv) a capability to hydrolyze X from N-CBZ-Ala-X wherein N-CBZ is N-carbobenzoxy and X is any amino acid;

(d) an allelic variant of (a) or (b); and

(e) a fragment of (a), (b) or (d), wherein the fragment retains carboxypeptidase activity.

The present invention also relates to isolated nucleic acid sequences encoding the polypeptides and to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.

The present invention also relates to methods of obtaining hydrolysates from proteinaceous substrates which comprise subjecting the proteinaceous material to a polypeptide with carboxypeptidase activity alone or in combination with an endopeptidase, and to hydrolysates obtained from the method.

The present invention also relates to methods of obtaining from a proteinaceous substrate a hydrolysate enriched in free glutamic acid and/or peptide bound glutamic acid residues, which methods comprise subjecting the substrate to a deamidation process and to the action of a polypeptide having carboxypeptidase activity.

The present invention further relates to flavor-improving compositions comprising a polypeptide with carboxypeptidase activity. The compositions may further comprise additional enzymatic activities.

In a final aspect, the methods of the invention may be used in food related applications to improve flavor, such as baking. Alternatively, flavor improvement in foods may be achieved by the addition of hydrolysates obtained by the methods of the invention.

Brief Description of the Figures

Figure 1 shows the dependence of *Aspergillus oryzae* ATCC 20386 carboxypeptidase I activity on pH.

Figure 2 shows the dependence of *Aspergillus oryzae* ATCC 20386 carboxypeptidase I activity on temperature.

Figure 3 shows the nucleic acid sequence and the deduced amino acid sequence of the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I (SEQ ID NOS:1 and 2).

Figure 4 shows a sequence comparison of the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I to that of other known carboxypeptidases.

Detailed Description of the Invention

Polypeptides Having Carboxypeptidase Activity

The term "carboxypeptidase activity" is defined herein as a peptidase activity which catalyzes the removal of amino acids from the C-terminus of peptides, oligopeptides or proteins. Defined in a general manner, the carboxypeptidase activity is capable of cleaving the amino acid X from the C-terminus of a peptide, polypeptide, or protein, wherein X represents any amino acid residue selected from the group consisting of Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val. It will be understood that the isolated polypeptides having carboxypeptidase activity of the present invention are unspecific as to the amino acid sequence of the peptide, polypeptide, or protein to be cleaved.

In a first embodiment, the present invention relates to isolated polypeptides having an amino acid sequence which has a degree of identity to the amino acid sequence of SEQ

ID NO:2 of at least about 50%, preferably at least about 60%, preferably at least about 70%, more preferably at least about 80%, even more preferably at least about 90%, most preferably at least about 95%, and even most preferably at least about 97%, which retain carboxypeptidase activity (hereinafter "homologous polypeptides"). In a preferred embodiment, the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from the amino acid sequence of SEQ ID NO:2. For purposes of the present invention, the degree of identity between two amino acid sequences is determined by the Clustal method (Higgins, 1989, *CABIOS* 5: 151-153) with an identity table, a gap penalty of 10, and a gap length penalty of 10.

Preferably, the polypeptides of the present invention comprise the amino acid sequence of SEQ ID NO:2 or an allelic variant and a fragment thereof, wherein the fragment retains carboxypeptidase activity. In a more preferred embodiment, the polypeptides of the present invention comprise the amino acid sequence of SEQ ID NO:2. In another preferred embodiment, the polypeptide of the present invention has the amino acid sequence of SEQ ID NO:2 or a fragment thereof, wherein the fragment retains carboxypeptidase activity. In a most preferred embodiment, the polypeptide has the amino acid sequence of SEQ ID NO:2.

Preferably, a fragment contains at least 300 amino acid residues, more preferably at least 400 amino acid residues, and most preferably at least 500 amino acid residues.

An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. The term allelic variant is also used to denote a protein encoded by an allelic variant of a gene.

The amino acid sequences of the homologous polypeptides may differ from the amino acid sequence of SEQ ID NO:2 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal

extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine and valine), aromatic amino acids (such as phenylalanine, tryptophan and tyrosine), and small amino acids (such as glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, *e.g.*, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

In a second embodiment, the present invention relates to isolated polypeptides having carboxypeptidase activity which are encoded by nucleic acid sequences which hybridize under low stringency conditions, more preferably medium stringency conditions and most preferably high stringency conditions, with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence of SEQ ID NO:1 or its complementary strand (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York); or allelic variants and fragments of the polypeptides.

Hybridization indicates that the nucleic acid sequence hybridizes to the oligonucleotide probe corresponding to the polypeptide encoding part of the nucleic acid sequence shown in SEQ ID NO:1, under low to high stringency conditions (*i.e.*, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 mg/ml sheared and denatured salmon sperm DNA, and either 25, 35 or 50% formamide for low, medium and high stringencies, respectively), following standard Southern blotting procedures.

The amino acid sequence of SEQ ID NO:2 or a partial amino acid sequence thereof may be used to design an oligonucleotide probe, or a nucleic acid sequence encoding a polypeptide of the present invention, such as the nucleic acid sequence of SEQ ID NO:1, or a subsequence thereof, may be used to identify and clone DNA encoding polypeptides having

carboxypeptidase activity from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 40 nucleotides in length. Longer probes can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with ^{32}P , ^3H , ^{35}S , biotin, or avidin).

Thus, a genomic, cDNA or combinatorial chemical library prepared from such other organisms may be screened for DNA which hybridizes with the probes described above and which encodes a polypeptide having carboxypeptidase activity. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA which is homologous with SEQ ID NO:1, the carrier material is used in a Southern blot in which the carrier material is finally washed three times for 30 minutes each using 2 x SSC, 0.2% SDS at a temperature of at least 50°C, more preferably at least 55°C, more preferably at least 60°C, more preferably at least 65°C, even more preferably at least 70°C, and most preferably at least 75°C. Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using X-ray film.

In a third embodiment, the present invention relates to isolated polypeptides having (i) optimal activity in the range of about pH 3.0 to about pH 7.5 at 25°C; (ii) optimal activity in the range of about 55°C to about 60°C at pH 4; (iii) a residual activity of at least about 65.5% after 30 minutes at pH 4.0 and 60°C; and (iv) a capability to hydrolyze N-CBZ-Ala-X wherein X is any amino acid. Preferably, the polypeptides have optimal activity at a pH in the range of about 4.0 to about 6.0 at 25°C and most preferably in the range of about 4.0 to about 5.0. The polypeptides also preferably have a molecular weight in the range of about 66 kDa to about 70 kDa by SDS-PAGE. Furthermore, the polypeptides preferably have a residual activity of at least about 60%, most preferably at least 65%, and most preferably a residual activity in the range of 50-85%, after 10 minutes at pH 4.0 and 60°C. The polypeptides of the present invention also preferably have a residual activity of at least about 70%, most preferably at least 75%, and most preferably a residual activity in

the range of 65-90%, after 30 minutes at pH 4.0 and 55°C. Preferably, the polypeptides are capable of hydrolyzing N-CBZ-Ala-X where X is Ile, Glu, Lys, Arg, Asp, Asn, Phe, or Tyr.

In a fourth embodiment, the present invention relates to isolated polypeptides having immunochemical identity or partial immunochemical identity to the polypeptide having the amino acid sequence of SEQ ID NO:2. The immunochemical properties are determined by immunological cross-reaction identity tests by the well-known Ouchterlony double immunodiffusion procedure. Specifically, an antiserum containing antibodies which are immunoreactive or bind to epitopes of the polypeptide having the amino acid sequence of SEQ ID NO:2 are prepared by immunizing rabbits (or other rodents) according to the procedure described by Harboe and Ingild, *In* N.H. Axelsen, J. Krøll, and B. Weeks, editors, *A Manual of Quantitative Immuno-electrophoresis*, Blackwell Scientific Publications, 1973, Chapter 23, or Johnstone and Thorpe, *Immunochemistry in Practice*, Blackwell Scientific Publications, 1982 (more specifically pages 27-31). A polypeptide having immunochemical identity is a polypeptide which reacts with the antiserum in an identical fashion such as total fusion of precipitates, identical precipitate morphology, and/or identical electrophoretic mobility using a specific immunochemical technique. A further explanation of immunochemical identity is described by Axelsen, Bock, and Krøll, *In* N.H. Axelsen, J. Krøll, and B. Weeks, editors, *A Manual of Quantitative Immuno-electrophoresis*, Blackwell Scientific Publications, 1973, Chapter 10. A polypeptide having partial immunochemical identity is a polypeptide which reacts with the antiserum in a partially identical fashion such as partial fusion of precipitates, partially identical precipitate morphology, and/or partially identical electrophoretic mobility using a specific immunochemical technique. A further explanation of partial immunochemical identity is described by Bock and Axelsen, *In* N.H. Axelsen, J. Krøll, and B. Weeks, editors, *A Manual of Quantitative Immuno-electrophoresis*, Blackwell Scientific Publications, 1973, Chapter 11.

Polypeptides encoded by nucleic acid sequences which hybridize with an oligonucleotide probe which hybridizes with the nucleic acid sequence of SEQ ID NO:1 or its complementary strand, or allelic variants and fragments of the polypeptides, the homologous polypeptides and polypeptides having identical or partially identical immunological properties may be obtained from microorganisms of any genus.

In a preferred embodiment, these polypeptides are obtained from a bacterial source. For example, these polypeptides may be obtained from a gram positive bacterium such as a

Bacillus strain, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* strain, e.g., *Streptomyces lividans* or *Streptomyces murinus*, or from a gram negative bacterium, e.g., *E. coli* or *Pseudomonas* sp.

In another preferred embodiment, these polypeptides are obtained from a fungal source. For example, the polypeptides may be obtained from a yeast strain, e.g., a *Candida*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* strain. In a preferred embodiment, the polypeptides are obtained from a *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* strain. The polypeptides may also be obtained from a filamentous fungal strain. For example, the polypeptides may be obtained from an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* strain. In a most preferred embodiment, the polypeptides are obtained from an *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochromum*, *Fusarium sulphureum*, *Fusarium toruloseum*, *Fusarium trichothecioides*, *Fusarium venenatum*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Thielavia terrestris*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* strain.

Furthermore, such polypeptides may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a genomic or cDNA library of another microorganism. Once a nucleic acid sequence encoding a polypeptide has been detected with the probe(s), the sequence may be isolated or

cloned by utilizing techniques which are known to those of ordinary skill in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

The polypeptides of the present invention are preferably obtained from species of *Aspergillus* including, but not limited to, *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, or *Aspergillus oryzae*. Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

In a more preferred embodiment, a polypeptide of the present invention is obtained from an *Aspergillus oryzae* strain, and most preferably from *Aspergillus oryzae* ATCC 20386 or a mutant strain thereof, *e.g.*, the polypeptide with the amino acid sequence of SEQ ID NO:2.

The polypeptides of the present invention may also be obtained from microorganisms which are synonyms of *Aspergillus* as defined by Raper, K.D. and Fennel, D.I., 1965, *The Genus Aspergillus*, The Wilkins Company, Baltimore. *Aspergilli* are mitosporic fungi characterized by an aspergillum comprised of a conidiospore stipe with no known teleomorphic states terminating in a vesicle, which in turn bears one or two layers of synchronously formed specialized cells, variously referred to as sterigmata or phialides, and asexually formed spores referred to as conidia. Known teleomorphs of *Aspergillus* include *Eurotium*, *Neosartorya*, and *Emericella*. Strains of *Aspergillus* and teleomorphs thereof are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the polypeptide is produced by the source or by a cell in which a gene from the source has been inserted.

As defined herein, an "isolated" polypeptide is a polypeptide which is essentially free of other non-carboxypeptidase polypeptides, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more preferably about 80% pure,

most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.

Nucleic Acid Sequences

5 The present invention also relates to isolated nucleic acid sequences which encode a polypeptide of the present invention. In a preferred embodiment, the nucleic acid sequence encodes a polypeptide obtained from *Aspergillus*, e.g., *Aspergillus oryzae*, and in a more preferred embodiment, the nucleic acid sequence is obtained from *Aspergillus oryzae* ATCC 20386, e.g., the nucleic acid sequence of SEQ ID NO:1. In another more preferred
10 embodiment, the nucleic acid sequence is the sequence contained in plasmid pEJG12 which is contained in *Escherichia coli* NRRL B-21616. The present invention also encompasses nucleic acid sequences which encode a polypeptide having the amino acid sequence of SEQ ID NO:2, which differ from SEQ ID NO:1 by virtue of the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NO:1 which encode fragments of SEQ ID NO:2 which retain carboxypeptidase activity. Preferably, a subsequence contains
15 at least 900 nucleotides, more preferably at least 1200 nucleotides, and most preferably at least 1500 nucleotides.

As described above, the nucleic acid sequences may be obtained from microorganisms which are synonyms or teleomorphs of *Aspergillus oryzae* as defined by Raper, K.D. and Fennel, D.I., 1965, *supra*.
20

The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis *et al.*, 1990, *PCR: A Guide to Methods and Application*, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used. The nucleic acid sequence may be
25 cloned from a strain of *Aspergillus*, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.
30

The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, *e.g.*, at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

The present invention also relates to nucleic acid sequences which have a degree of homology to the nucleic acid sequence of SEQ ID NO:1 of at least about 50%, preferably about 60%, preferably about 70%, preferably about 80%, more preferably about 90%, even more preferably about 95%, and most preferably about 97% homology, which encode an active polypeptide. For purposes of the present invention, the degree of homology between two nucleic acid sequences is determined by the Clustal method (Higgins, 1989, *supra*) with an identity table, a gap penalty of 10, and a gap length penalty of 10.

Modification of a nucleic acid sequence encoding a polypeptide of the present invention may be necessary for the synthesis of polypeptides substantially similar to the polypeptide. The term "substantially similar" to the polypeptide refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source. For example, it may be of interest to synthesize variants of the polypeptide where the variants differ in specific activity, thermostability, pH optimum, or the like using, *e.g.*, site-directed mutagenesis. The analogous sequence may be constructed on the basis of the nucleic acid sequence presented as the polypeptide encoding part of SEQ ID NO:1, *e.g.*, a subsequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but which corresponds to the codon usage of the host organism intended for production of the enzyme, or by introduction of

nucleotide substitutions which may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, *e.g.*, Ford *et al.*, 1991, *Protein Expression and Purification* 2: 95-107.

It will be apparent to those skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acid residues essential to the activity of the polypeptide encoded by the isolated nucleic acid sequence of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, *e.g.*, Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for carboxypeptidase activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of the three-dimensional structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, *e.g.*, de Vos *et al.*, 1992, *Science* 255: 306-312; Smith *et al.*, 1992, *Journal of Molecular Biology* 224: 899-904; Wlodaver *et al.*, 1992, *FEBS Letters* 309: 59-64).

Polypeptides of the present invention also include fused polypeptides or cleavable fusion polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding another polypeptide to a nucleic acid sequence (or a portion thereof) of the present invention. Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under control of the same promoter(s) and terminator.

The present invention also relates to isolated nucleic acid sequences encoding a polypeptide of the present invention, which hybridize under low stringency conditions, more preferably medium stringency conditions and most preferably high stringency conditions, with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence of SEQ ID NO:1 or its complementary strand; or allelic variants and subsequences thereof (Sambrook *et al.*, 1989, *supra*).

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a nucleic acid sequence of the present invention operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding sequence" as defined herein is a sequence which is transcribed into mRNA and translated into a polypeptide of the present invention when placed under the control of the above mentioned control sequences. The boundaries of the coding sequence are generally determined by a translation start codon ATG at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

An isolated nucleic acid sequence encoding a polypeptide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleic acid sequence encoding a polypeptide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.

The term "control sequences" is defined herein to include all components which are necessary or advantageous for the expression of a polypeptide of the present invention. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the

control sequences with the coding region of the nucleic acid sequence encoding a polypeptide. The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to the coding sequence of the DNA sequence such that the control sequence directs the production of a polypeptide.

5 The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences which mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid
10 promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli lac* operon, the *Streptomyces coelicolor* agarase gene (*dagA*), the *Bacillus subtilis* levansucrase gene (*sacB*), the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), the *Bacillus licheniformis* penicillinase gene (*penP*), the *Bacillus subtilis* *xylA* and *xylB* genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 3727-3731), as well as the *tac* promoter (DeBoer *et al.*, 1983, *Proceedings of the National Academy of Sciences USA* 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242: 74-94; and in Sambrook *et al.*, 1989, *supra*.
20

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium oxysporum* trypsin-like protease (as described in
25 U.S. Patent No. 4,288,627, which is incorporated herein by reference), and mutant, truncated, and hybrid promoters thereof. Particularly preferred promoters for use in
30

filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral α -amylase and *Aspergillus oryzae* triose phosphate isomerase), and *glaA* promoters.

In a yeast host, useful promoters are obtained from the *Saccharomyces cerevisiae* enolase (ENO-1) gene, the *Saccharomyces cerevisiae* galactokinase gene (GAL1), the *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the *Saccharomyces cerevisiae* 3-phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by Romanos *et al.*, 1992, *Yeast* 8: 423-488. In a mammalian host cell, useful promoters include viral promoters such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus, and bovine papilloma virus (BPV).

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

Preferred terminators for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* α -glucosidase, and *Fusarium oxysporum* trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes encoding *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), or *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos *et al.*, 1992, *supra*. Terminator sequences are well known in the art for mammalian host cells.

The control sequence may also be a suitable leader sequence, a nontranslated region of a mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence which is functional in the host cell of choice may be used in the present invention.

Preferred leaders for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase and *Aspergillus oryzae* triose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the *Saccharomyces cerevisiae* enolase (ENO-1) gene, the *Saccharomyces cerevisiae* 3-phosphoglycerate kinase gene, the *Saccharomyces cerevisiae* alpha-factor, and the *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, and *Aspergillus niger* alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Molecular Cellular Biology* 15: 5983-5990. Polyadenylation sequences are well known in the art for mammalian host cells.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the polypeptide. The signal peptide coding region may be obtained from a glucoamylase or an amylase gene from an *Aspergillus* species, a lipase or proteinase gene from a *Rhizomucor* species, the gene for the alpha-factor from *Saccharomyces cerevisiae*, an amylase or a protease gene from a *Bacillus* species, or the calf preprochymosin gene. However, any

signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

An effective signal peptide coding region for bacterial host cells is the signal peptide coding region obtained from the maltogenic amylase gene from *Bacillus* NCIB 11837, the *Bacillus stearothermophilus* alpha-amylase gene, the *Bacillus licheniformis* subtilisin gene, the *Bacillus licheniformis* beta-lactamase gene, the *Bacillus stearothermophilus* neutral proteases genes (*nprT*, *nprS*, *nprM*), and the *Bacillus subtilis* PrsA gene. Further signal peptides are described by Simonen and Palva, 1993, *Microbiological Reviews* 57: 109-137.

An effective signal peptide coding region for filamentous fungal host cells is the signal peptide coding region obtained from *Aspergillus oryzae* TAKA amylase gene, *Aspergillus niger* neutral amylase gene, the *Rhizomucor miehei* aspartic proteinase gene, the *Humicola lanuginosa* cellulase gene, or the *Rhizomucor miehei* lipase gene.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding regions are described by Romanos *et al.*, 1992, *supra*.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (*aprE*), the *Bacillus subtilis* neutral protease gene (*nprT*), the *Saccharomyces cerevisiae* alpha-factor gene, or the *Myceliophthora thermophila* laccase gene (WO 95/33836).

The nucleic acid constructs of the present invention may also comprise one or more nucleic acid sequences which encode one or more factors that are advantageous for directing the expression of the polypeptide, *e.g.*, an activator (*e.g.*, a *trans*-acting factor), a chaperone, and a processing protease. Any factor that is functional in the host cell of choice may be used in the present invention. The nucleic acids encoding one or more of these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.

An activator is a protein which activates transcription of a nucleic acid sequence encoding a polypeptide (Kudla *et al.*, 1990, *EMBO Journal* 9: 1355-1364; Jarai and Buxton, 1994, *Current Genetics* 26: 2238-244; Verdier, 1990, *Yeast* 6: 271-297). The nucleic acid

sequence encoding an activator may be obtained from the genes encoding *Bacillus*
stearothermophilus NprA (*nprA*), *Saccharomyces cerevisiae* heme activator protein 1 (*hap1*),
Saccharomyces cerevisiae galactose metabolizing protein 4 (*gal4*), and *Aspergillus nidulans*
ammonia regulation protein (*areA*). For further examples, see Verdier, 1990, *supra* and
5 MacKenzie *et al.*, 1993, *Journal of General Microbiology* 139: 2295-2307.

A chaperone is a protein which assists another polypeptide in folding properly (Hartl
et al., 1994, *TIBS* 19: 20-25; Bergeron *et al.*, 1994, *TIBS* 19: 124-128; Demolder *et al.*,
1994, *Journal of Biotechnology* 32: 179-189; Craig, 1993, *Science* 260: 1902-1903; Gething
and Sambrook, 1992, *Nature* 355: 33-45; Puig and Gilbert, 1994, *Journal of Biological*
10 *Chemistry* 269: 7764-7771; Wang and Tsou, 1993, *The FASEB Journal* 7: 1515-11157;
Robinson *et al.*, 1994, *Bio/Technology* 1: 381-384). The nucleic acid sequence encoding a
chaperone may be obtained from the genes encoding *Bacillus subtilis* GroE proteins,
Aspergillus oryzae protein disulphide isomerase, *Saccharomyces cerevisiae* calnexin,
Saccharomyces cerevisiae BiP/GRP78, and *Saccharomyces cerevisiae* Hsp70. For further
15 examples, see Gething and Sambrook, 1992, *supra*, and Hartl *et al.*, 1994, *supra*.

A processing protease is a protease that cleaves a propeptide to generate a mature
biochemically active polypeptide (Enderlin and Ogrydziak, 1994, *Yeast* 10: 67-79; Fuller *et*
al., 1989, *Proceedings of the National Academy of Sciences USA* 86: 1434-1438; Julius *et*
al., 1984, *Cell* 37: 1075-1089; Julius *et al.*, 1983, *Cell* 32: 839-852). The nucleic acid
20 sequence encoding a processing protease may be obtained from the genes encoding
Saccharomyces cerevisiae dipeptidylaminopeptidase, *Saccharomyces cerevisiae* Kex2, and
Yarrowia lipolytica dibasic processing endoprotease (*xpr6*).

It may also be desirable to add regulatory sequences which allow the regulation of the
expression of the polypeptide relative to the growth of the host cell. Examples of regulatory
25 systems are those which cause the expression of the gene to be turned on or off in response
to a chemical or physical stimulus, including the presence of a regulatory compound.
Regulatory systems in prokaryotic systems would include the *lac*, *tac*, and *trp* operator
systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi,
the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and the
30 *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other
examples of regulatory sequences are those which allow for gene amplification. In
eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the

presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be operably linked with the regulatory sequence.

5 Expression Vectors

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals,

prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. A frequently used mammalian marker is the dihydrofolate reductase gene. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. A selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), *trpC* (anthranilate synthase), and glufosinate resistance markers, as well as equivalents from other species. Preferred for use in an *Aspergillus* cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygroscopicus*. Furthermore, selection may be accomplished by co-transformation, *e.g.*, as described in WO 91/17243, where the selectable marker is on a separate vector.

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

The vectors of the present invention may be integrated into the host cell genome when introduced into a host cell. For integration, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell

by non-homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAMB1 permitting replication in *Bacillus*. Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, *e.g.*, Ehrlich, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1433).

More than one copy of a nucleic acid sequence encoding a polypeptide of the present invention may be inserted into the host cell to amplify expression of the nucleic acid sequence. Stable amplification of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by culturing the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due to mutations that occur during replication.

The cell is preferably transformed with a vector comprising a nucleic acid sequence of the invention followed by integration of the vector into the host chromosome.

“Transformation” means introducing a vector comprising a nucleic acid sequence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.

The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism, *e.g.*, a prokaryote, or a non-unicellular microorganism, *e.g.*, a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, *e.g.*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, *e.g.*, *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas* sp. In a preferred embodiment, the bacterial host cell is a *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus* or *Bacillus subtilis* cell. The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, *e.g.*, Chang and Cohen, 1979, *Molecular General Genetics* 168: 111-115), by using competent cells (see, *e.g.*, Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209-221), by electroporation (see, *e.g.*, Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or by conjugation (see, *e.g.*, Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

The host cell may be a eukaryote, such as a mammalian cell, an insect cell, a plant cell or a fungal cell. Useful mammalian cells include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, COS cells, or any number of other immortalized cell lines available, *e.g.*, from the American Type Culture Collection.

In a preferred embodiment, the host cell is a fungal cell. “Fungi” as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth *et al.*, In, *Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth *et al.*, 1995, *supra*, page 171) and all mitosporic fungi

(Hawksworth *et al.*, 1995, *supra*). Representative groups of Ascomycota include, *e.g.*, *Neurospora*, *Eupenicillium* (= *Penicillium*), *Emericella* (= *Aspergillus*), *Eurotium* (= *Aspergillus*), and the true yeasts listed below. Examples of Basidiomycota include mushrooms, rusts, and smuts. Representative groups of Chytridiomycota include, *e.g.*, *Allomyces*, *Blastocladiella*, *Coelomomyces*, and aquatic fungi. Representative groups of Oomycota include, *e.g.*, Saprolegniomycetous aquatic fungi (water molds) such as *Achlya*. Examples of mitosporic fungi include *Aspergillus*, *Penicillium*, *Candida*, and *Alternaria*. Representative groups of Zygomycota include, *e.g.*, *Rhizopus* and *Mucor*.

In a preferred embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporeogenous yeast (Endomycetales), basidiosporeogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). The ascosporeogenous yeasts are divided into the families Spermophthoraceae and Saccharomycetaceae. The latter is comprised of four subfamilies, Schizosaccharomycoideae (*e.g.*, genus *Schizosaccharomyces*), Nadsonioideae, Lipomycoideae, and Saccharomycoideae (*e.g.*, genera *Kluyveromyces*, *Pichia*, and *Saccharomyces*). The basidiosporeogenous yeasts include the genera *Leucosporidium*, *Rhodospodium*, *Sporidiobolus*, *Filobasidium*, and *Filobasidiella*. Yeast belonging to the Fungi Imperfecti are divided into two families, Sporobolomycetaceae (*e.g.*, genera *Sorobolomyces* and *Bullera*) and Cryptococcaceae (*e.g.*, genus *Candida*). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980. The biology of yeast and manipulation of yeast genetics are well known in the art (see, *e.g.*, *Biochemistry and Genetics of Yeast*, Bacil, M., Horecker, B.J., and Stopani, A.O.M., editors, 2nd edition, 1987; *The Yeasts*, Rose, A.H., and Harrison, J.S., editors, 2nd edition, 1987; and *The Molecular Biology of the Yeast Saccharomyces*, Strathern *et al.*, editors, 1981).

In a more preferred embodiment, the yeast host cell is a cell of a species of *Candida*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia*.

In a most preferred embodiment, the yeast host cell is a *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis*

cell. In another most preferred embodiment, the yeast host cell is a *Kluyveromyces lactis* cell. In another most preferred embodiment, the yeast host cell is a *Yarrowia lipolytica* cell.

In a preferred embodiment, the fungal host cell is a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative. In a more preferred embodiment, the filamentous fungal host cell is a cell of a species of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolytocladium*, and *Trichoderma*.

In an even more preferred embodiment, the filamentous fungal host cell is an *Aspergillus* cell. In another even more preferred embodiment, the filamentous fungal host cell is an *Acremonium* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Fusarium* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Humicola* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Mucor* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Myceliophthora* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Neurospora* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Penicillium* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Thielavia* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Tolytocladium* cell. In another even more preferred embodiment, the filamentous fungal host cell is a *Trichoderma* cell.

In a most preferred embodiment, the filamentous fungal host cell is an *Aspergillus* *awamori*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger* or *Aspergillus oryzae* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Fusarium bacridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sulphureum*, *Fusarium toruloseum*, *Fusarium*

trichothecioides, or *Fusarium venenatum* cell. In an even most preferred embodiment, the filamentous fungal parent cell is a *Fusarium venenatum* (Nirenberg sp. nov.). In another most preferred embodiment, the filamentous fungal host cell is a *Humicola insolens* or *Humicola lanuginosa* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Mucor miehei* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Myceliophthora thermophilum* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Neurospora crassa* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Penicillium purpurogenum* cell. In another most preferred embodiment, the filamentous fungal host cell is a *Thielavia terrestris* cell. In another most preferred embodiment, the *Trichoderma* cell is a *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei* or *Trichoderma viride* cell.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. A suitable method of transforming *Fusarium* species is described by Malardier *et al.*, 1989, *Gene* 78: 147-156 or in WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology*, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; and Hinnen *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920. Mammalian cells may be transformed by direct uptake using the calcium phosphate precipitation method of Graham and Van der Eb (1978, *Virology* 52: 546).

Methods of Production

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a strain, which in its wild-type form is capable of producing the polypeptide, to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide. Preferably, the strain is of the genus *Aspergillus*.

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

In both methods, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art (see, *e.g.*, references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, *More Gene Manipulations in Fungi*, Academic Press, CA, 1991). Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it is recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide. Procedures for determining carboxypeptidase activity are known in the art and include, *e.g.*, *o*-phthaldialdehyde together with dithiothreitol to monitor the liberation of free amino acids under enzymatic hydrolysis according to the procedure of Roth, 1971, *Analytical Chemistry* 43: 880.

The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing (IEF), differential solubility (*e.g.*, ammonium sulfate

precipitation), SDS-PAGE, or extraction (see, *e.g.*, *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

Removal or reduction of carboxypeptidase activity

5 The present invention also relates to methods for producing a mutant cell of a parent cell, which comprises disrupting or deleting a nucleic acid sequence encoding the polypeptide or a control sequence thereof, which results in the mutant cell producing less of the polypeptide than the parent cell.

10 The construction of strains which have reduced carboxypeptidase activity may be conveniently accomplished by modification or inactivation of a nucleic acid sequence necessary for expression of the polypeptide having carboxypeptidase activity in the cell. The nucleic acid sequence to be modified or inactivated may be, for example, a nucleic acid sequence encoding the polypeptide or a part thereof essential for exhibiting carboxypeptidase activity, or the nucleic acid sequence may have a regulatory function required for the expression of the polypeptide from the coding sequence of the nucleic acid sequence. An example of such a regulatory or control sequence may be a promoter sequence or a functional part thereof, *i.e.*, a part which is sufficient for affecting expression of the polypeptide. Other control sequences for possible modification are described above.

20 Modification or inactivation of the nucleic acid sequence may be performed by subjecting the cell to mutagenesis and selecting for cells in which the carboxypeptidase producing capability has been reduced. The mutagenesis, which may be specific or random, may be performed, for example, by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, the mutagenesis may be performed by use of any
25 combination of these mutagenizing agents.

 Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.

30 When such agents are used, the mutagenesis is typically performed by incubating the cell to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions, and selecting for cells exhibiting reduced carboxypeptidase activity or production.

Modification or inactivation of production of a polypeptide of the present invention may be accomplished by introduction, substitution or removal of one or more nucleotides in the nucleic acid sequence encoding the polypeptide or a regulatory element required for the transcription or translation thereof. For example, nucleotides may be inserted or removed so as to result in the introduction of a stop codon, the removal of the start codon, or a change of the open reading frame. Such modification or inactivation may be accomplished by site-directed mutagenesis or PCR generated mutagenesis in accordance with methods known in the art. Although, in principle, the modification may be performed *in vivo*, *i.e.*, directly on the cell expressing the nucleic acid sequence to be modified, it is preferred that the modification be performed *in vitro* as exemplified below.

An example of a convenient way to inactivate or reduce production by a host cell of choice is based on techniques of gene replacement or gene interruption. For example, in the gene interruption method, a nucleic acid sequence corresponding to the endogenous gene or gene fragment of interest is mutagenized *in vitro* to produce a defective nucleic acid sequence which is then transformed into the host cell to produce a defective gene. By homologous recombination, the defective nucleic acid sequence replaces the endogenous gene or gene fragment. It may be desirable that the defective gene or gene fragment also encodes a marker which may be used for selection of transformants in which the gene encoding the polypeptide has been modified or destroyed.

Alternatively, modification or inactivation of the nucleic acid sequence encoding a polypeptide of the present invention may be performed by established anti-sense techniques using a nucleotide sequence complementary to the polypeptide encoding sequence. More specifically, production of the polypeptide by a cell may be reduced or eliminated by introducing a nucleotide sequence complementary to the nucleic acid sequence encoding the polypeptide which may be transcribed in the cell and is capable of hybridizing to the polypeptide mRNA produced in the cell. Under conditions allowing the complementary anti-sense nucleotide sequence to hybridize to the polypeptide mRNA, the amount of polypeptide translated is thus reduced or eliminated.

It is preferred that the cell to be modified in accordance with the methods of the present invention is of microbial origin, for example, a fungal strain which is suitable for the production of desired protein products, either homologous or heterologous to the cell.

The present invention further relates to a mutant cell of a parent cell which comprises a disruption or deletion of a nucleic acid sequence encoding the polypeptide or a control sequence thereof, which results in the mutant cell producing less of the polypeptide than the parent cell.

5 The polypeptide-deficient mutant cells so created are particularly useful as host cells for the expression of homologous and/or heterologous polypeptides. Therefore, the present invention further relates to methods for producing a homologous or heterologous polypeptide comprising (a) culturing the mutant cell under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide. In the present context, the term
10 "heterologous polypeptides" is defined herein as polypeptides which are not native to the host cell, a native protein in which modifications have been made to alter the native sequence, or a native protein whose expression is quantitatively altered as a result of a manipulation of the host cell by recombinant DNA techniques.

In a still further aspect, the present invention relates to a method for producing a protein product essentially free of carboxypeptidase activity by fermentation of a cell which produces both a polypeptide of the present invention as well as the protein product of interest. The method comprises adding an effective amount of an agent capable of inhibiting carboxypeptidase activity to the fermentation broth either during or after the fermentation has been completed, recovering the product of interest from the fermentation broth, and
20 optionally subjecting the recovered product to further purification. This method is further illustrated in the examples below.

In a still further alternative aspect, the present invention relates to a method for producing a protein product essentially free of carboxypeptidase activity, wherein the protein product of interest is encoded by a DNA sequence present in a cell encoding a polypeptide
25 of the present invention. The method comprises cultivating the cell under conditions permitting the expression of the product, subjecting the resultant culture broth to a combined pH and temperature treatment so as to reduce the carboxypeptidase activity substantially, and recovering the product from the culture broth. Alternatively, the combined pH and temperature treatment may be performed on an enzyme preparation recovered from the culture broth. The combined pH and temperature treatment may optionally be used in
30 combination with a treatment with a carboxypeptidase inhibitor.

In accordance with this aspect of the invention, it is possible to remove at least 60%, preferably at least 75%, more preferably at least 85%, still more preferably at least 95%, and most preferably at least 99% of the carboxypeptidase activity. It is contemplated that a complete removal of carboxypeptidase activity may be obtained by use of this method.

5 The combined pH and temperature treatment is preferably carried out at a pH in the range of 6.5-7 and a temperature in the range of 25-40°C for a sufficient period of time to attain the desired effect, where typically, 30 to 60 minutes is sufficient.

The methods used for cultivation and purification of the product of interest may be performed by methods known in the art.

10 The methods of the present invention for producing an essentially carboxypeptidase-free product is of particular interest in the production of eukaryotic polypeptides, in particular fungal proteins such as enzymes. The enzyme may be selected from, *e.g.*, an amylolytic enzyme, a lipolytic enzyme, a proteolytic enzyme, a cellulytic enzyme, an oxidoreductase or a plant cell-wall degrading enzyme. Examples of such enzymes include
15 an aminopeptidase, an amylase, an amyloglucosidase, a carbohydase, a carboxypeptidase, a catalase, a cellulase, a chitinase, a cutinase, a cyclodextrin glycosyltransferase, a deoxyribonuclease, an esterase, a galactosidase, a beta-galactosidase, a glucoamylase, a glucose oxidase, a glucosidase, a haloperoxidase, a hemicellulase, an invertase, an isomerase, a laccase, a ligase, a lipase, a lyase, a mannosidase, an oxidase, a pectinolytic enzyme, a peroxidase, a phytase, a phenoloxidase, a polyphenoloxidase, a proteolytic enzyme, a
20 ribonuclease, a transferase, a transglutaminase, or a xylanase. The carboxypeptidase-deficient cells may also be used to express heterologous proteins of pharmaceutical interest such as hormones, growth factors, receptors, and the like.

25 It will be understood that the term "eukaryotic polypeptides" includes not only native polypeptides, but also those polypeptides, *e.g.*, enzymes, which have been modified by amino acid substitutions, deletions or additions, or other such modifications to enhance activity, thermostability, pH tolerance and the like.

In a further aspect, the present invention relates to a protein product essentially free from carboxypeptidase activity which is produced by a method of the present invention.

30 Methods of Producing Protein Hydrolysates

The polypeptides of the present invention may be used in the production of protein hydrolysates for enhancing the degree of hydrolysis and flavor development.

The present invention further relates to methods for the use of a polypeptide of the present invention in combination with an endopeptidase to produce a high degree of hydrolysis of a protein-rich material. The method comprises treatment of a proteinaceous substrate with the polypeptide and an endopeptidase. The substrate may be treated with the enzymes concurrently or consecutively.

A polypeptide of the present invention is added to the proteinaceous substrate in an effective amount conventionally employed in protein hydrolysis processes, preferably in the range of from about 0.1 to about 100,000 CPDU per 100 g of protein, and more preferably in the range of from about 1 to about 10,000 CPDU per 100 g of protein. As defined herein, one CPDU (carboxypeptidase unit) is the amount of carboxypeptidase which liberates 1 micromole of glutamate per minute from a 0.5 mM N-CBZ-Ala-Glu (Sigma Chemical Co., St. Louis MO) solution at pH 4.5 and 25°C.

The endopeptidase may be obtained from a strain of *Bacillus*, preferably *Bacillus licheniformis* or *Bacillus subtilis*, a strain of *Staphylococcus*, preferably *Staphylococcus aureus*, a strain of *Streptomyces*, preferably *Streptomyces thermovularis* or *Streptomyces griseus*, a strain of *Actinomyces* species, a strain of *Aspergillus*, preferably *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus nidulans*, *Aspergillus niger*, or *Aspergillus oryzae*, or a strain of *Fusarium*, preferably *Fusarium venenatum*.

The endopeptidase is added to the proteinaceous substrate in an effective amount conventionally employed in protein hydrolysis processes, preferably in the range of from about 0.05 to about 15 AU/100 g of protein, and more preferably from about 0.1 to about 8 AU/100 g of protein. One AU (Anson Unit) is defined as the amount of enzyme which under standard conditions (*i.e.*, 25°C, pH 7.5 and 10 min. reaction time) digests hemoglobin at an initial rate such that there is liberated per minute an amount of TCA soluble product which gives the same color with phenol reagent as one milli-equivalent of tyrosine. The analytical method AF 4/5 is available upon request from Novo Nordisk A/S, Denmark, which is incorporated herein by reference.

The enzymatic treatment, *i.e.*, the incubation of the substrate with the enzyme preparations, may take place at any convenient temperature at which the enzyme preparation does not become inactivated, preferably in the range of from about 20°C to about 70°C. In

accordance with established practice, the enzyme preparations may be suitably inactivated by increasing the temperature of the incubation mixture to a temperature where the enzymes become inactivated, *e.g.*, to above about 70°C, or similarly by decreasing the pH of the incubation mixture to a point where the enzymes become inactivated, *e.g.*, below about 4.0.

5 Furthermore, the methods of the present invention result in enhancement of the degree of hydrolysis of a proteinaceous substrate. As used herein, the degree of hydrolysis (DH) is the percentage of the total number of amino bonds in a protein that has been hydrolyzed by a proteolytic enzyme.

10 In another aspect of the present invention, the hydrolysates have an increased content of Leu, Gly, Ala, and/or Pro, *e.g.*, 1.1 times greater.

The present invention also relates to methods of obtaining a hydrolysate enriched in free glutamic acid and/or peptide bound glutamic acid residues, which method comprises:

- (a) subjecting the substrate to a deamidation process; and
- (b) subjecting the substrate to the action of a polypeptide having carboxypeptidase activity.

The two steps may be performed simultaneously, or the second step may be performed subsequent to the first step.

20 These methods of the present invention produce protein hydrolysates of excellent flavor because glutamic acid (Glu), whether free or peptide bound, plays an important role in the flavor and palatability of protein hydrolysates. These method also produce protein hydrolysates having improved functionality, in particular, improved solubility, improved emulsifying properties, increased degree of hydrolysis, and improved foaming properties.

25 The conversion of amides (glutamine or asparagine) into charged acids (glutamic acid or aspartic acid) via the liberation of ammonia is known as deamidation. Deamidation may take place as a non-enzymatic or as an enzymatic deamidation process.

In a preferred embodiment, the deamidation is carried out as an enzymatic deamidation process, *e.g.*, by subjecting the substrate to a transglutaminase and/or peptidoglutaminase.

30 The transglutaminase may be of any convenient source including mammals, see *e.g.*, JP 1050382 and JP 5023182, including activated Factor XIII, see *e.g.*, WO 93/15234; those derived from fish, see *e.g.*, EP 555,649; and those obtained from microorganisms, see *e.g.*, EP 379,606, WO 96/06931 and WO 96/22366. In a preferred embodiment, the

transglutaminase is obtained from an Oomycete, including a strain of *Phytophthora*, preferably *Phytophthora cactorum*, or a strain of *Pythium*, preferably *Pythium irregulare*, *Pythium* sp., *Pythium intermedium*, *Pythium ultimum*, or *Pythium periplocum* (or *Pythium periplocum*). In another preferred embodiment, the transglutaminase is of bacterial origin and is obtained from a strain of *Bacillus*, preferably *Bacillus subtilis*, a strain of *Streptovercillium*, preferably *Streptovercillium mobaraensis*, *Streptovercillium griseocarneum*, or *Streptovercillium cinnamoneum*, and a strain of *Streptomyces*, preferably *Streptomyces lydicus*.

The peptidoglutaminase may be a peptidoglutaminase I (peptidyl-glutaminase; EC 3.5.1.43), or a peptidoglutaminase II (protein-glutamine glutaminase; EC 3.5.1.44), or any mixture thereof. The peptidoglutaminase may be obtained from a strain of *Aspergillus*, preferably *Aspergillus japonicus*, a strain of *Bacillus*, preferably *Bacillus circulans*, a strain of *Cryptococcus*, preferably *Cryptococcus albidus*, or a strain of *Debaryomyces*, preferably *Debaryomyces hansenii*.

The transglutaminase is added to the proteinaceous substrate in an effective amount conventionally employed in deamidation processes, preferably in the range of from about 0.01 to about 5% (w/w), and more preferably in the range of from about 0.1 to about 1% (w/w) of enzyme preparation relating to the amount of substrate.

The peptidoglutaminase is added to the proteinaceous substrate in an effective amount conventionally employed in deamidation processes, preferably in the range of from about 0.01 to about 100,000 PGase Units per 100 g of substrate, and more preferably in the range of from about 0.1 to about 10,000 PGase Units per 100 g of substrate.

The peptidoglutaminase activity may be determined according to the procedure of Cedrangoro *et al.* (1965, *Enzymologia* 29: 143). According to this procedure, 0.5 ml of an enzyme sample, adjusted to pH 6.5 with 1 N NaOH, is charged into a small vessel. Then 1 ml of a borate pH 10.8 buffer solution is added to the vessel. The discharged ammonia is absorbed by 5 N sulphuric acid, and by use of Nessler's reagent the mixture is allowed to form color which is measured at 420 nm. One PGase unit is the amount of enzyme capable of producing 1 micromole of ammonia per minute under these conditions.

Alternatively, the peptidoglutaminase activity may be determined according to the procedure described in US 3,857,967 or Example 11 below.

In step (b) of the methods of the present invention, the substrate is subjected to a polypeptide of the present invention. A polypeptide of the present invention is added to the proteinaceous substrate in an effective amount conventionally employed in protein hydrolysis processes, preferably in the range of from about 0.001 to about 0.5 AU/100 g of substrate, more preferably in the range of from about 0.01 to about 0.1 AU/100 g of substrate.

In another embodiment, the methods of the present invention for producing a hydrolysate enriched in free glutamic acid and/or peptide bound glutamic acid residues further comprise:

(c) subjecting the substrate to one or more unspecific acting endo- and/or exo-peptidase enzymes.

This step may take place simultaneously with steps (a) and (b), or may follow steps (a) and (b).

In a preferred embodiment, the unspecific acting endo- and/or exo-peptidase enzyme is obtained from a strain of *Aspergillus*, preferably *Aspergillus niger*, *Aspergillus oryzae*, or *Aspergillus sojae*, or a strain of *Bacillus*, preferably *Bacillus amyloliquefaciens*, *Bacillus lentus*, *Bacillus licheniformis*, or *Bacillus subtilis*.

The unspecific acting endo- and/or exo-peptidase enzyme is added to the substrate in an effective amount conventionally employed in protein hydrolysis processes, preferably in the range of from about 0.05 to about 15 CPU/100 g of substrate, and more preferably in the range of from about 0.1 to about 5 CPU/100 g of substrate. One CPU (Casein Protease Unit) is defined as the amount of enzyme liberating 1 micromole of primary amino groups (determined by comparison with a serine standard) per minute from casein under standard conditions, *i.e.*, incubation for 30 minutes at 25°C and pH 9.5. The analytical method AF 228/1, which is incorporated herein by reference, is available upon request from Novo Nordisk A/S, Bagsværd, Denmark.

Each enzymatic treatment may take place at any temperature at which the enzyme preparation does not become inactivated, preferably in the range of from about 20°C to about 70°C. The enzyme preparation may then be inactivated by increasing the temperature, *e.g.*, to above about 70°C, or by decreasing the pH, *e.g.*, below about 4.0.

The proteinaceous substrate used in the methods of the present invention may consist of intact proteins, prehydrolyzed proteins (*i.e.*, peptides), or a mixture thereof. The proteinaceous substrate may be of vegetable or animal origin. Preferably, the proteinaceous

substrate is of vegetable origin, *e.g.*, soy protein, grain protein, *e.g.*, wheat gluten, corn gluten, barley, rye, oat, rice, zein, lupine, cotton seed protein, rape seed protein, peanut, alfalfa protein, pea protein, fabaceous bean protein, sesame seed protein, or sunflower. A proteinaceous substrate of animal origin may be whey protein, casein, meat proteins, fish protein, red blood cells, egg white, gelatin, or lactoalbumin.

The present invention also relates to protein hydrolysates produced by these methods.

Other Uses

The present invention also relates to methods of deactivating enzymes with a polypeptide of the present invention.

Furthermore, a polypeptide of the present invention may be useful for a number of purposes in which a specific cleavage of peptide sequences is desirable. For instance, some proteins or peptides are synthesized in the form of inactive precursors comprising a number of additional amino acid residues at the N-terminal of the mature protein. A polypeptide of the present invention could provide the necessary post-translational processing to activate such precursor proteins.

Polypeptide Compositions

In a still further aspect, the present invention relates to polypeptide compositions comprising a polypeptide of the present invention. Preferably, the compositions are enriched in a polypeptide of the present invention. In the present context, the term "enriched" indicates that the carboxypeptidase activity of the polypeptide composition has been increased, *e.g.*, with an enrichment factor of 1.1.

The polypeptide composition may comprise a polypeptide of the invention as the major enzymatic component, *e.g.*, a mono-component polypeptide composition. Alternatively, the composition may comprise multiple enzymatic activities, such as an aminopeptidase, an amylase, a carbohydrase, a carboxypeptidase, a catalase, a cellulase, a chitinase, a cutinase, a cyclodextrin glycosyltransferase, a deoxyribonuclease, an esterase, an alpha-galactosidase, a beta-galactosidase, a glucoamylase, an alpha-glucosidase, a beta-glucosidase, a haloperoxidase, an invertase, a laccase, a lipase, a mannosidase, an oxidase, a pectinolytic enzyme, a peptidoglutaminase, a peroxidase, a phytase, a polyphenoloxidase, a proteolytic enzyme, a ribonuclease, a transglutaminase, or a xylanase. The additional

enzyme(s) may be producible by means of a microorganism belonging to the genus *Aspergillus*, preferably *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus niger*, or *Aspergillus oryzae*, or *Trichoderma*, *Humicola*, preferably *Humicola insolens*, or *Fusarium*, preferably *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sulphureum*, *Fusarium toruloseum*, *Fusarium trichothecioides*, or *Fusarium venenatum*.

In a preferred embodiment, the invention relates to a flavor-improving composition comprising a polypeptide with carboxypeptidase activity. In another preferred embodiment, the flavor-improving composition further comprises an endopeptidase. In another preferred embodiment, the flavoring composition further comprises one or more unspecific-acting endo- and/or exo-peptidase enzymes. In another preferred embodiment, the flavoring composition further comprises one or more specific-acting endo- and/or exo-peptidase enzymes.

In a preferred embodiment, the specific acting proteolytic enzyme is an endopeptidase such as a glutamyl endopeptidase (EC 3.4.21.19); a lysyl endopeptidase (EC 3.4.21.50); a leucyl endopeptidase (EC 3.4.21.57); a glycyl endopeptidase (EC 3.4.22.25); a prolyl endopeptidase (EC 3.4.21.26); trypsin (EC 3.4.21.4) or a trypsin-like (lysine/arginine specific) endopeptidase; or a peptidyl-Asp metalloendopeptidase (EC 3.4.24.33).

The glutamyl endopeptidase (EC 3.4.21.19) may preferably be obtained from a strain of *Bacillus*, in particular *Bacillus licheniformis* and *Bacillus subtilis*, a strain of *Staphylococcus*, in particular *Staphylococcus aureus*, a strain of *Streptomyces*, in particular *Streptomyces thermovulgaris* and *Streptomyces griseus*, or a strain of *Actinomyces sp.*

The lysyl endopeptidase (EC 3.4.21.50) may preferably be obtained from a strain of *Achromobacter*, in particular *Achromobacter lyticus*, a strain of *Lysobacter*, in particular *Lysobacter enzymogenes*, or a strain of *Pseudomonas*, in particular *Pseudomonas aeruginosa*.

The leucyl endopeptidase (EC 3.4.21.57) may be of plant origin.

The glycyl endopeptidase (EC 3.4.22.25) may preferably be obtained from the papaya plant (*Carica papaya*).

The prolyl endopeptidase (EC 3.4.21.26) may preferably be obtained from a strain of *Flavobacterium*, or it may be of plant origin.

The trypsin-like endopeptidase may preferably be obtained from a strain of *Fusarium*, in particular *Fusarium oxysporum*, e.g., as described in WO 89/06270 or WO 94/25583.

The peptidyl-Asp metalloendopeptidase (EC 3.4.24.33) may preferably be obtained from a strain of *Pseudomonas*, in particular *Pseudomonas fragi*.

In another preferred embodiment, the specific acting proteolytic enzyme is an exopeptidase that may act from either end of the peptide.

In a preferred embodiment, the specific acting proteolytic enzyme is an aminopeptidase such as a leucyl aminopeptidase (EC 3.4.11.1); or a tripeptide aminopeptidase (EC 3.4.11.4).

In another preferred embodiment, the specific acting proteolytic enzyme is a carboxypeptidase such as a proline carboxypeptidase (EC 3.4.16.2); a carboxypeptidase A (EC 3.4.17.1); a carboxypeptidase B (EC 3.4.17.2); a carboxypeptidase C (EC 3.4.16.5); a carboxypeptidase D (EC 3.4.16.6); a lysine (arginine) carboxypeptidase (EC 3.4.17.3); a glycine carboxypeptidase (EC 3.4.17.4); an alanine carboxypeptidase (EC 3.4.17.6); a glutamate carboxypeptidase (EC 3.4.17.11); a peptidyl-dipeptidase A (EC 3.4.15.1); or a peptidyl-dipeptidase (EC 3.4.15.5).

The polypeptide compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. The polypeptide may be stabilized by methods known in the art.

The present invention also relates to food products, e.g., baked products, comprising a protein hydrolysate obtained by the methods of the present invention. Such food products exhibit enhanced organoleptic qualities, such as improvement in flavor, palatability, mouth feel, aroma and crust color.

In the present context, the term "baked products" includes any food prepared from dough, either of a soft or a crisp character. Examples of baked products, whether of a white, light or dark type, which may be advantageously produced by the present invention, are bread, in particular white, whole-meal or rye bread, typically in the form of loaves or rolls; French baguette-type breads; pita breads; tacos; cakes; pancakes; biscuits; crisp breads; and the like.

Such baked products are conventionally prepared from a dough which comprises flour and water, and which is typically leavened. The dough may be leavened in various ways, such as by adding sodium bicarbonate or the like, or by adding a leaven (fermenting dough),

but the dough is preferably leavened by adding a suitable yeast culture such as a culture of *Saccharomyces cerevisiae* (baker's yeast). Any of the commercially available *Saccharomyces cerevisiae* strains may be employed.

Further, the dough used in the preparation of the baked products may be fresh or frozen. The preparation of frozen dough is described by K. Kulp and K. Lorenz in "Frozen and Refrigerated Doughs and Batters". A flavor improving composition of the present invention is typically included in the dough in an amount in the range of 0.01-5%, more preferably 0.1-3%.

In the methods of the present invention, a polypeptide of the present invention, an endopeptidase, a transglutaminase, a peptidoglutaminase, one or more specific and/or unspecific acting endo- and/or exo-peptidase enzymes, and/or one or more enzymes specified above may be added, either separately or concurrently, to the mixture from which the dough is made or to any ingredient, *e.g.*, flour, from which the dough is to be made.

The present invention further relates to a pre-mix, *e.g.*, in the form of a flour composition, for dough and/or baked products made from dough, wherein the pre-mix comprises a flavor-improving composition of the invention and optionally one or more other enzymes specified above.

In another embodiment, the pre-mix comprises a hydrolysate obtained by the methods of the invention.

The pre-mix may be prepared by mixing the relevant enzymes with a suitable carrier such as flour, starch, a sugar or a salt. The pre-mix may contain other dough-improving and/or bread-improving additives.

In the present context, the term "pre-mix" is a mixture of baking agents, normally including flour, which has been prepared to permit storage under designated conditions and provide convenience in handling during dough preparation processes. Such a pre-mix may be of advantageous use in industrial and commercial bread-baking plants and facilities, as well as in retail bakeries.

The present invention also relates to the use of a hydrolysate produced by the methods of the invention as an additive to food products, such as baked foods, to enhance organoleptic qualities, such as flavor, palatability and aroma.

The hydrolysates enriched in free glutamic acid and/or peptide bound glutamic acid residues obtained by the methods of the present invention may be used in various industrial applications, in particular, where there is a need for the incorporation of functional proteins.

For example, the present invention also relates to food products comprising a hydrolysate enriched in free glutamic acid and/or peptide bound glutamic acid residues obtained by the method of the invention and to animal feed additives comprising a hydrolysate enriched in free glutamic acid and/or peptide bound glutamic acid residues obtained by the methods of the present invention.

The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

Examples

Materials

Chemicals used as buffers and substrates are commercial products of at least reagent grade.

Example 1: Purification of FLAVOURZYME™ carboxypeptidase I

Carboxypeptidase was purified from a FLAVOURZYME™ broth (Novo Nordisk A/S, Bagsværd, Denmark). First, the broth (20 ml; 720 mg protein) was diluted with 180 ml of 20 mM sodium phosphate pH 7.0 buffer and filtered using Nalgene Filterware equipped with a 0.45 mm filter. The filtered solution was loaded onto a 24 x 130 mm column containing 31 ml of Q-Sepharose, Big Beads ("Pharmacia Biotech AB", Uppsala, Sweden) pre-equilibrated with 20 mM sodium phosphate pH 7.0 buffer. The carboxypeptidase was eluted using a pH gradient from 7.0 (20 mM sodium phosphate buffer) to 5.0 (20 mM sodium acetate buffer) and then from 5.0 to 3.6 (20 mM sodium acetate buffer). Carboxypeptidase activity was monitored at 340 nm using 1.5 mM furylacryloyl-Ala-Lys as substrate at 50 mM sodium phosphate pH 6.0 buffer. Fractions between pH 4.3 and 3.6 were collected, pooled, and concentrated to 25 ml using ultrafiltration (Diaflo membranes, 10PK).

The concentrated solution was diluted with 100 ml of 20 mM sodium phosphate pH 7.0 buffer and then loaded onto a 20 x 100 mm column containing MonoQ Beads ("Pharmacia Biotech AB", Uppsala, Sweden) pre-equilibrated with 20 mM sodium phosphate pH 7.0 buffer. The carboxypeptidase was eluted with a 0 to 1 M NaCl gradient in 20 mM

sodium phosphate pH 7.0 buffer. Fractions were monitored for carboxypeptidase activity as described above. The fractions between 0.10 and 0.13 M NaCl were collected, pooled, and concentrated using ultrafiltration against 20 mM sodium acetate pH 4.0 buffer.

The purified preparation was estimated to be at least 95% homogeneous based on SDS PAGE analysis. The major band was found to have a molecular weight of approximately 68 kDa (range of 66-70 kDa).

Example 2: Protein sequencing and amino acid analysis methods

N-terminal sequencing of the purified carboxypeptidase and a degraded fragment of the carboxypeptidase from the broth of Example 1 was performed on an Applied Biosystems 476A Protein Sequencer (Perkin Elmer/Applied Biosystems Division, Foster City, CA) with on-line HPLC and liquid phase trifluoroacetic acid (TFA) delivery. Samples of the purified carboxypeptidase were transblotted onto Novex PVDF membranes (Novex, San Diego, CA) from SDS-PAGE gels and sequenced from a blott cartridge using sequencing reagents (Perkin Elmer/Applied Biosystems Division, Foster City, CA). Detection of phenylthiohydantoin-amino acids was accomplished by on-line HPLC using Buffer A containing 3.5% tetrahydrofuran in water with 15-30 mls of the Premix concentrate (Perkin Elmer/Applied Biosystems Division, Foster City, CA) containing acetic acid, sodium acetate, and sodium hexanesulfonate and Buffer B containing acetonitrile. Data was collected and analyzed on a Macintosh IIsi using Applied Biosystems 610 Data Analysis software.

The purified carboxypeptidase was also subjected to cyanogen bromide to generate peptide fragments of the enzyme for sequencing. The carboxypeptidase was digested with cyanogen bromide by reconstituting a dried sample of the purified carboxypeptidase in 70% formic acid with a few crystals of cyanogen bromide and incubating for 18 hours at room temperature in the dark. The peptide fragments were separated by SDS-PAGE electrophoresis using 10-20% Novex Tricine gels (Novex, San Diego, CA) and sequenced as described above.

N-terminal sequencing of the carboxypeptidase reveals that the N-terminus was blocked. The degraded fragment has the following amino acid sequence where amino acid residues in parentheses are not 100% certain and residues marked with a ? could not be determined. Amino acid residues underlined match 100% with the carboxypeptidase S1 from *Penicillium janthienellum*:

Peptide 1: ?YGGHYGPAF(F)NH(F)(Y)(E)(Q)(N)E(R) (SEQ ID NO:3)

Sequencing of the cyanogen bromide fragments showed the following peptide fragment sequences which are 30-40% homologous to the carboxypeptidase from *Penicillium janthinellum* (Svendsen *et al.*, 1993, *FEBS Letters* 333: 39-43):

Peptide 2 (50 kDa): DAIGVNI?YTQ?NNDVYYA (SEQ ID NO:4)

Peptide 3 (42 kDa): DAIGVNI(N)YTQSNN(D)VYYAFQQTGDFVWPNFIEDL (SEQ ID NO:5)

Peptide 4 (17 kDa): (?C)RDNVEGP(?)YAFAGRGVYDIRHPYD(P)(D)(T) (SEQ ID NO:6)

Example 3: Characterization of purified carboxypeptidase I

Inhibition of the carboxypeptidase with 1,10-phenanthroline and phenylmethylsulfonyl fluoride was evaluated using furylacryloyl-Ala-Lys as substrate at pH 7.0 in 20 mM phosphate buffer where hydrolysis was monitored at 340 nm.

The results indicate that 1,10-phenanthroline does not inhibit the carboxypeptidase activity. On the other hand, phenylmethylsulfonyl fluoride inhibits carboxypeptidase activity completely at pH 7.0 using furylacryloyl-Ala-Lys as a substrate. These results suggest that the carboxypeptidase was a serine protease.

Using N-CBZ-Ala-Ile as substrate in 50 mM sodium acetate buffer (pHs 4-7.5) and 50 mM citric acid/KH₂PO₄ buffer (pHs 2.9 and 3.9), the pH dependence of the bimolecular constant k_{cat}/K_m at 25°C was a bell-shaped curve with a pronounced optimum at pH 4.0-4.5 (Figure 1). The slope of the right and the left branches of the curve appears to be -1 and 1, respectively, which indirectly shows that the active center of the enzyme contains two ionogenic groups with pK values of 3.3 and 5.7.

The dependence of temperature on the activity of the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I was determined using N-CBZ-Ala-Ile as substrate in 50 mM sodium acetate pH 4 buffer. The results as shown in Figure 2 indicate optimal activity is observed at a temperature in the range of about 55°C to about 60°C at pH 4.

The substrate specificity of the carboxypeptidase was determined by measuring the hydrolysis of a substrate listed in Table 1 at pH 4.0 in 50 mM acetate buffer. *o*-Phthaldialdehyde together with dithiothreitol were used to monitor the liberation of free Ile, Glu, Lys, Arg, Asp, Asn, Gly, Phe, and Tyr under enzymatic hydrolysis according to the procedure of Roth, M., 1971, *Analytical Chemistry* 43: 880. The k_{cat} value for the

hydrolysis of N-CBZ-Ala-X or N-CBZ-Glu-X was determined based on the assumption that molecular weight of the carboxypeptidase was 68 kD and that the enzyme preparation was homogeneous.

The carboxypeptidase was determined to have very broad substrate specificity where no preference for aromatic, bulky aliphatic, or polar carboxyl-terminal amino acid residues was observed. The best substrates of the carboxypeptidase, N-CBZ-Ala-Glu, N-CBZ-Ala-Ile, N-CBZ-Ala-Lys, N-CBZ-Ala-Arg, and N-CBZ-Ala-Asn, have very different terminal amino acid residues but similar values of all kinetic parameters for the specific hydrolysis at pH 4.0 (Table 1).

Table 1. Substrate specificity of the carboxypeptidase.

Substrate	$K_m \cdot 10^3$ (M)	k_{cat}^b (s^{-1})	$k_{cat}/K_m \cdot 10^3$ ($M^{-1} s^{-1}$)
N-CBZ-Ala-Ile	0.11	24	218
N-CBZ-Ala-Glu	0.10	32	320
N-CBZ-Ala-Lys	0.12	32	270
N-CBZ-Ala-Arg	0.11	27	246
N-CBZ-Ala-Asp	0.27	27	100
N-CBZ-Ala-Asn	0.09	19	216
N-CBZ-Ala-Gly	0.92	5.5	6
N-CBZ-Ala-Phe	0.24	17	72
N-CBZ-Ala-Tyr	0.09	17.5	194
N-CBZ-Glu-Tyr	0.11	4.7	43

The carboxypeptidase also was able to cleave Pro from N-CBZ-Ala-Pro. However, the specificity of the enzyme to this substrate was low. Only 16% of a 2 mM N-CBZ-Ala-Pro solution was hydrolyzed after a 2 hour incubation with a very high concentration (4.9×10^{-7} M) of the carboxypeptidase. N-CBZ-Ala-Phe was a good substrate for the carboxypeptidase. The value of k_{cat} was at least 8.5-fold higher than that for the acid carboxypeptidases O-1 and O-2 from *Aspergillus oryzae*. (Takeuchi and Ichishima, 1981, *Agric. Biol. Chem.* 45: 1033, Takeuchi *et al.*, 1982, *Current Microbiology* 7: 19).

The K_m value of the carboxypeptidase toward furylacryloyl-Ala-Lys was 0.4 mM at pH 4.0, 25°C.

The carboxypeptidase also possesses high thermostability. A 10 minute incubation of the enzyme in 50 mM acetate buffer at pH 4.0 and 60°C results in a 65 % residual activity

compared to the 37 kDa carboxypeptidase from *Aspergillus oryzae* which was completely inactivated at this temperature (Azarenkova *et al.*, 1976, *Biokhimiya* 41: 20). A 10 minute incubation of the enzyme in 50 mM acetate buffer at pH 4.0 and 55°C results in a 74% residual activity.

5 The activity of the carboxypeptidase was determined by measuring the rate of specific hydrolysis of N-CBZ-Ala-Glu. One carboxypeptidase unit (CPDU) is the amount of carboxypeptidase which liberates 1 micromole of glutamate per minute from a 0.5 mM N-CBZ-Ala-Glu solution at pH 4.5 and 25°C. A reagent containing *o*-phthaldialdehyde in combination with dithiothreitol was used to monitor the liberation of free glutamate under
10 enzymatic hydrolysis according to the procedure of Roth, 1971, *supra*. The *o*-phthaldialdehyde reagent was a solution of *o*-phthaldialdehyde (6 mM) and dithiothreitol (6.5 mM) in 0.1 M sodium tetraborate. Briefly, 0.05 ml of the enzyme solution in 20 mM acetate buffer, pH 4.5 was incubated with 1 ml of substrate. At regular time intervals, a 0.3 ml aliquot was withdrawn, mixed with 0.9 ml of the *o*-phthaldialdehyde reagent, and the absorption at A_{340} , using a path length of 1 cm, of the resultant product was measured. Where the dependence of A_{340} on the incubation time was linear, the specific activity of the enzyme was calculated using the equation: specific activity = slope (optical density per min) x 11.35. By this procedure, the specific activity of the purified carboxypeptidase was determined to be 11 CPDU per mg protein which is equivalent to 11 micromoles glutamate per minute per mg protein.
20

Example 4: RNA isolation

Aspergillus oryzae strain ATCC 20386 was cultivated in a fermentation tank in a medium comprised of 7.5 g of potato starch, 10 g of soy bean meal, 2 g of KH_2PO_4 , 5 g of $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$, and 0.1 g of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ per liter. A two liter sample was taken after five
25 days of growth at 30°C, and the mycelia were collected, frozen in liquid N_2 , and stored at -80°C. Total RNA was prepared from the frozen, powdered mycelium of *Aspergillus oryzae* ATCC 20386 by extraction with guanidinium thiocyanate followed by ultracentrifugation through a 5.7 M cesium chloride cushion (Chirgwin *et al.*, 1979, *Biochemistry* 18: 5294-5299). Poly(A)+ RNA was isolated by oligo(dT)-cellulose affinity chromatography according to Aviv and Leder (1972, *Proceedings of the National Academy of Sciences USA* 69: 1408-1412).
30

Example 5: Construction of a cDNA library

Double-stranded cDNA was synthesized from 5 µg of *Aspergillus oryzae* ATCC 20386 poly(A)+ RNA of Example 4 as described by Gubler and Hoffman (1983, *Gene* 25: 263-269) and Sambrook *et al.* (1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, New York), except that an oligo(dT)-*Not*I anchor primer, instead of an oligo(dT)12-18 primer, was used in the first strand reaction. After synthesis, the cDNA was treated with Mung bean nuclease (Life Technologies, Gaithersburg, MD), blunt-ended with T4 DNA polymerase (Boehringer Mannheim, Indianapolis, IN), and ligated to non-palindromic *Bst*XI adaptors (Invitrogen, San Diego, CA), using about 50-fold molar excess of the adaptors. The adapted cDNA was digested with *Not*I, size-fractionated for 1.2-3.0 kb cDNAs by agarose gel electrophoresis, and ligated into *Bst*XI/*Not*I cleaved pYES2.0 vector (Invitrogen, San Diego, CA). The ligation mixture was used to transform electrocompetent *E. coli* DH10B cells (Life Technologies, Gaithersburg, MD) according to the manufacturer's instructions. The library consisting of 1 x 10⁶ independent clones was stored as individual pools (25,000-30,000 colony forming units/pool) in 20% glycerol at -80°C, and as double stranded cDNA and ligation mixture at -20°C.

Example 6: PCR amplification of *Aspergillus oryzae* ATCC 20386 carboxypeptidase I

Based on the amino acid sequences of the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I partial peptides described in Example 2, the degenerate oligonucleotide primers shown below were synthesized with an Applied Biosystems Model 394 DNA/RNA Synthesizer, according to the manufacturer's instructions, for use to PCR amplify carboxypeptidase I gene fragments from *Aspergillus oryzae* ATCC 20386:

Forward primer: 5'-TAYGGNGGICAYTAYGGICCNG-3' (SEQ ID NO:7)

Reverse primer: 5'-ATRAARTTIGGCCAIACRAARTC-3' (SEQ ID NO:8)

(R= A or G, Y= C or T, N= G or A or C or T, I= Inosine)

Amplification reactions (100 µl) were prepared using approximately 1 µg of isolated plasmids from an *Aspergillus oryzae* ATCC 20386 cDNA library of Example 5 as the template. Each reaction contains the following components: 1 µg plasmids, 40 pmol forward primer, 40 pmol reverse primer, 200 µM each of dATP, dCTP, dGTP, and dTTP, 1 x *Taq* polymerase buffer (Perkin-Elmer Corp., Branchburg, NJ), and 2.5 Units of *Taq* polymerase (Perkin-Elmer Corp., Branchburg, NJ). The reactions were incubated in a

Perkin-Elmer Model 480 Thermal Cycler programmed as follows: Cycle 1 - 95°C for 5 minutes, 45°C for 2 minutes, and 67°C for 2 minutes; and Cycles 2-30 - 95°C for 2 minutes; 45°C for one minute, and 67°C for 2 minutes. The reaction products were isolated on a 1% agarose gel (Eastman Kodak, Rochester, NY). The 550 bp product band was excised from the gel and purified using GenElute spin columns (Supelco, Bellefonte, PA) according to the manufacturer's instructions. The purified PCR products were subsequently cloned into a pCRII vector (Invitrogen, San Diego, CA) and the DNA sequences were determined using lac forward and reverse primers (New England BioLabs, Beverly, MA).

A carboxypeptidase I gene segment consisting of approximately 186 codons (550 bp) was amplified from *Aspergillus oryzae* ATCC 20386 as shown in Figure 1 with the carboxypeptidase-specific PCR primers described above. DNA sequence analysis shows that the amplified gene segment encodes a portion of the corresponding *Aspergillus oryzae* ATCC 20386 carboxypeptidase I gene. The carboxypeptidase I gene segment was used to probe an *Aspergillus oryzae* ATCC 20386 cDNA library.

Example 7: Identification of carboxypeptidase I clones

The *Aspergillus oryzae* ATCC 20386 cDNA library was plated on Luria agar plates supplemented with 50 mg/ml carbenicillin. Colony lifts (Maniatis *et al.*, 1982, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, New York) were performed on approximately 5,000 colonies and the DNA was cross-linked onto membranes (Hybond N+, Amersham, Arlington Heights, IL) using a UV Stratalinker (Stratagene, La Jolla, CA). The membranes were soaked for three hours at 45°C in a hybridization solution containing 5 x SSPE, 0.3% SDS, 50% formamide, and 10 mg/ml of denatured and sheared herring sperm DNA. The carboxypeptidase I gene fragment isolated from the *Aspergillus oryzae* ATCC 20386 as described in Example 1 was radiolabeled using the Random Primed DNA Labeling Kit (Boehringer Mannheim, Mannheim, Germany), denatured by adding NaOH to a final concentration of 0.1M, and added to the hybridization solution at an activity of approximately 1 x 10⁶ cpm per ml of hybridization solution. The mixture was incubated overnight at 45°C in a shaking water bath. Following incubation, the membranes were washed once in 2 x SSC with 0.2% SDS at 55°C followed by two washes in 2 x SSC at the same temperature. The membranes were dried on blotting paper for 15

minutes, wrapped in SaranWrap™, and exposed to X-ray film overnight at -70°C with intensifying screens (Kodak, Rochester, NY).

Six colonies, designated *E. coli* DH5a clones EJG12, EJG12A, EJG12B, EJG12C, EJG12D, and EJG12E, produced strong hybridization signals with the probe. The six colonies were inoculated into three ml of LB+ 50 µg/ml carbenicillin medium and grown overnight at 37°C. Miniprep DNA was prepared from each of these clones using the Wizard 373 DNA Purification Kit (Promega, Madison, WI). The carboxypeptidase encoding plasmids were confirmed by DNA sequencing.

Example 8: DNA sequence analysis of *Aspergillus oryzae* ATCC 20386 carboxypeptidase I gene

DNA sequencing of the carboxypeptidase I clone (*E. coli* DH5a EJG12) described in Example 2 was performed with an Applied Biosystems Model 373A Automated DNA Sequencer (Applied Biosystems, Inc., Foster City, CA) on both strands using the primer walking technique with dye-terminator chemistry (Giesecke *et al.*, 1992, *Journal of Virology Methods* 38: 47-60). Oligonucleotide sequencing primers were designed to complementary sequences in the carboxypeptidase I gene and were synthesized on an Applied Biosystems Model 394 DNA/RNA Synthesizer according to the manufacturer's instructions.

The nucleotide sequence of the gene encoding the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I cDNA is shown in Figure 3 (SEQ ID NO:1). Sequence analysis of the cloned insert revealed a large open reading frame of 1665 nucleotides (excluding the stop codon) encoding a protein of 555 amino acids. The G+C content of this open reading frame was 52.1%. Based on the rules of van Heijne (van Heijne, 1984, *Journal of Molecular Biology* 173: 243-251), the first 18 amino acids likely comprise a secretory signal peptide which directs the nascent polypeptide into the endoplasmic reticulum (double underlined in Figure 3).

The deduced amino acid sequence of the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I as shown in Figure 3 (SEQ ID NO:2) indicates that the calculated molecular weight of the primary translation product is 61.2 kDa which is consistent with the estimate of 68 kDa based on the mobility of the purified protein on SDS-PAGE. Amino acid sequences of peptides obtained from the purified carboxypeptidase I as described in Example

2 are underlined in Figure 3 and consistent with those found in the deduced amino acid sequence of the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I cDNA.

Using the Clustal alignment program (Higgins, 1989, *CABIOS* 5: 151-153) to compare the deduced amino acid sequence of the *Aspergillus oryzae* ATCC 20386 carboxypeptidase I to that of other fungal carboxypeptidases reported in the literature, a 38.8% identity is observed compared to the *Penicillium janthinellum* carboxypeptidase S1 (Svendsen *et al.*, 1993, *supra*) (SEQ ID NO:9), 13.3% identity to the *Penicillium janthinellum* carboxypeptidase S3 (Svendsen and Day, 1995, *FEBS Letters* 371: 1-3) (SEQ ID NO:10), 16.4% identity to the *Aspergillus phoenicis* carboxypeptidase (Chiba *et al.*, 1995, *Biochemical Journal* 308: 405-409) (SEQ ID NO:11), and 14.7% identity to the *Aspergillus niger* carboxypeptidase (van den Hombergh *et al.*, 1994, *Gene* 151: 73-79) (SEQ ID NO:12), as shown in Figure 4. The deduced amino acid sequence for *Aspergillus oryzae* carboxypeptidase I has a catalytic triad comprising Asp-His-Ser (starred in Figure 4), which is conserved among serine carboxypeptidases.

Example 9: Cross-hybridization studies using genomic DNA from other fungi

The cloned *Aspergillus oryzae* ATCC 20386 carboxypeptidase gene was used as a probe in Southern hybridization experiments with genomic DNA samples from a variety of fungal genera. Southern blots were probed under conditions of low stringency (25% formamide, 5 X SSPE, 0.3% SDS at 45°C), medium stringency (35% formamide, 5 X SSPE, 0.3% SDS at 45°C) and high stringency (50% formamide, 5 X SSPE, 0.3% SDS at 45°C). Genomic DNA samples were isolated from the following species using the protocol outlined below: *Aspergillus niger* (Bo-95), *Aspergillus oryzae* (A1560), *Penicillium purpurogenum* (A3191), *Penicillium rubrum* (CBS 433.62), *Humicola grisea* var. *thermoidea* (ATCC 16453), *Botrytis cinerea* (ATCC 11542), *Curvularia verruculosa* (CBS 147.63), *Rhizoctonia solani* (IMI 358730), *Trichoderma harzianum* (CBS 819.68), *Absidia griseola* (ATCC 22618), *Myrothecium verrucaria* (ATCC 9095), *Myceliophthora thermophila* (CBS 117.65), and *Penicillium varians* (CBS 386.48).

Each of the strains described above was grown in 25 ml of 0.5% yeast extract-2% glucose (YEG) medium for 24 hours at 32°C and 250 rpm. Mycelia were then collected by filtration through Miracloth (Calbiochem, La Jolla, CA) and washed once with 25 ml of 10 mM Tris-1 mM EDTA (TE) buffer. Excess buffer was drained from the mycelia which were

subsequently frozen in liquid nitrogen. The frozen mycelia were ground to a fine powder in an electric coffee grinder, and the powders were added to 20 ml of TE buffer and 5 ml of 20% w/v sodium dodecylsulfate (SDS) in a disposable plastic centrifuge tube. The mixtures were gently inverted several times to insure mixing, and extracted twice with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v). Sodium acetate (3 M solution) was added to a final concentration of 0.3 M followed by addition of 2.5 volumes of ice cold ethanol to precipitate the nucleic acids. The nucleic acids were then pelleted by centrifuging the tube at 15,000 x g for 30 minutes. The pellets were allowed to air dry for 30 minutes before resuspension in 0.5 ml of TE buffer. DNase-free ribonuclease A was added to a concentration of 100 mg/ml and the mixtures were incubated at 37°C for 30 minutes. Proteinase K was then added at a concentration of 200 mg/ml and the mixtures were incubated an additional hour at 37°C. Finally, the mixtures were extracted twice with phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) before precipitating the DNA with sodium acetate and ethanol as described earlier. The DNA pellets were dried under vacuum, resuspended in TE buffer, and stored at 4°C until further use.

Each DNA sample (ca. 5 micrograms) was digested with *Bam*HI and *Eco*RI prior to electrophoresis on a 1% agarose gel. The DNA was blotted to Zeta-Probe nylon membrane (BioRad Laboratories, Hercules, CA) and probed with a nick translated DNA probe comprising the carboxypeptidase I gene. The blots were washed for 30 minutes in 2 X SSC + 0.2% SDS at 45°C, and for 30 minutes in 2 X SSC (no SDS). The washed filter was exposed to X-ray film overnight at -70°C with intensifying screens.

The carboxypeptidase gene from *Aspergillus oryzae* ATCC 20286 cross-hybridized with probable carboxypeptidase gene sequences in several other fungal species (Table 2). Under conditions of low stringency strong hybridization signals were apparent in DNAs from *Aspergillus oryzae* A1560, *Aspergillus niger*, and *Botrytis cinerea*. Weaker signals were detected in *Curvularia verruculosa*, *Humicola grisea* var. *thermoidea*, *Myrothecium verrucaria*, and *Trichoderma harzianum*. No hybridization was detected in *Absidia griseola*, *Myceliophthora thermophila*, *Penicillium purpurogenum*, *Penicillium rubrum*, *Penicillium varians*, or *Rhizoctonia solani*. Using medium stringency, strong hybridization signals were visible with only *Aspergillus oryzae* A1560 and *Botrytis cinerea*. Weak hybridization was observed with DNAs from *Aspergillus niger*, *Curvularia verruculosa*, *Humicola grisea* var. *thermoidea*, and *Myrothecium verrucaria*. Under high stringency conditions, only DNA from

Aspergillus oryzae A1560 hybridized with the carboxypeptidase gene probe. These data indicated that the *Aspergillus oryzae* ATCC 20286 carboxypeptidase gene can be used as a probe to clone carboxypeptidase genes from other filamentous fungi.

Table 2. Hybridization of genomic DNA samples from various fungi probed with the cloned *Aspergillus oryzae* ATCC 20286 carboxypeptidase gene. A +++ denotes a strong positive hybridization signal, + denotes a weak signal, and - denotes no detectable hybridization.

Genomic DNA Source	Low Stringency	Medium Stringency	High Stringency
<i>Absidia griseola</i>	-	-	-
<i>Aspergillus niger</i>	+++	+	-
<i>Aspergillus oryzae</i> A1560	+++	+++	+++
<i>Botrytis cinerea</i>	+++	+++	-
<i>Curvularia verruculosa</i>	+	-	-
<i>Humicola grisea</i> var. <i>thermoidea</i>	+	+	-
<i>Myceliophthora thermophila</i>	-	-	-
<i>Myrothecium verrucaria</i>	+	+	-
<i>Penicillium purpurogenum</i>	-	-	-
<i>Penicillium rubrum</i>	-	-	-
<i>Penicillium varians</i>	-	-	-
<i>Rhizoctonia solani</i>	-	-	-
<i>Trichoderma harzianum</i>	+	-	-

Example 10: Protein hydrolysis by a polypeptide having carboxypeptidase activity

Commercial grade soy meal, wheat gluten, casein and gelatin were used as protein substrates. The soy meal was prepared from defatted toasted soy grits 20/80/20 (Cargill BV, NL); vital wheat gluten was obtained from Crespel and Dieters, Denmark; casein was obtained as Na-Caseinate Miprodan (MD Foods, Denmark); and gelatin was obtained as Bonegelatin (DGF Stores, Denmark).

The substrates were prepared as a 2% (w/v) aqueous solution, in which the protein concentration was determined by the method of Kjeldahl. Two hundred mg of each substrate, obtained in the form of a dry composition, was dissolved in 9 ml of tap water and the pH was adjusted to 7.0. One ml of an enzyme solution was added containing either FLAVOURZYME™ (3 LAPU), carboxypeptidase (11.5 CPDU), or the combination of the two. The reaction mixture was incubated for 18 hours at 50°C. The enzymes were then inactivated by heating to 85°C for 3 minutes.

The hydrolysates were cooled and the degree of hydrolysis (DH) was assayed in microtiter plates using OPA (ortho-phthaldialdehyde, Sigma Chemical Co., St. Louis, MO) as the detecting reagent. The DH, defined as described in by Adler-Nissen (1986, *Enzymic Hydrolysis of Food Proteins*, Elsevier Applied Science Publishers), was determined by reaction of the supernatant with OPA (ortho-phthaldialdehyde, Sigma Chemical Co., St. Louis, MO). For the OPA reagent, 160 mg of OPA was dissolved in 4 ml of ethanol and transferred to a 200 ml volumetric flask containing a solution of 7.62 g of disodium tetraborate decahydrate, 200 mg of sodium dodecylsulphate, and 176 mg of dithiothreitol and the flask was filled to 200 ml with water.

A volume of 25 μ l of suitably diluted supernatant was mixed with 200 μ l of OPA reagent in a microtiter plate well and allowed to react for exactly 2 minutes at 25°C. The absorbance at 340 nm was measured in a microtiter plate reader and compared to the absorbance of a 95 mM L-serine standard solution after subtraction of the blank value (water reacted with OPA-reagent). To determine the true DH, the serine equivalents measured in the supernatants were corrected with the factors suggested by Adler-Nissen for the trinitrobenzenesulfonic acid method (Adler-Nissen, 1979, *Agricultural and Food Chemistry* 17: 1256) which gave the same response as the described OPA method. The degree of hydrolysis was calculated on basis of the total amount of protein in the hydrolysis mixture (not on basis of soluble protein).

The results, summarized in Table 3 below, indicate that for all substrates carboxypeptidase alone has no effect, but when added with FLAVOURZYME™ enhanced the DH obtained by FLAVOURZYME™.

Table 3

Substrate	Casein	Gelatin	Soy Meal	Wheat Gluten
Enzyme	DH	DH	DH	DH
FLAVOURZYME	44.8	20.2	36	41
Carboxypeptidase	0	0	0	0
Flavourzyme + Carboxypeptidase	50.2	22.9	40	45.6

Example 11: Increased protein solubility and release of glutamate by deamidation

Wheat gluten (WG) was obtained from Cargill (JOB 5141) and deamidated wheat gluten (DWG) was obtained from StaPro Consultancy B.V., Lemdijk 32, 9422 TH Smilde, NL. Suspensions of 8% protein were made by mixing 11 g of gluten with 89 g of water.

The pH was adjusted to 6.5 with NaOH. Glutamate/aspartate specific protease (SP446), obtainable as described in WO 91/13554, or lysine/arginine specific protease (SP387) obtainable as described in WO 89/06270, was added to the suspensions. The dosage was 0.01 AU/g protein for SP446 and 0.006 AU/g protein for SP387. FLAVOURZYME™ was added to some of the hydrolysates at a dosage of 20 LAPU/g protein. One LAPU (Leucine Amino Peptidase Unit) is the amount of enzyme which decomposes 1 micromole of L-leucine-p-nitroanilide per minute under the following conditions: 26 mM L-leucine-p-nitroanilide in 0.1 M Tris pH 8.0 buffer at 40°C for 10 minutes. Upon hydrolysis, p-nitroanilide is liberated turning the solution yellow which is monitored 405 nm.

The hydrolyses were carried out at 50°C without further pH adjustment for 18 hours. The enzymes were inactivated by heating at 85°C for 15 minutes. The pH was adjusted to 5 and the hydrolysates were centrifuged. The content of protein and free glutamate in the supernatant was determined.

The protein content was determined by Kjeldahl analysis, using a Kjeldahl factor of 6.25.

The content of free glutamate was determined by use of a glutamate determination kit according to the manufacturer's instructions (Boehringer-Mannheim, Indianapolis, IN). The method was adapted for use in microtiter plates.

When comparing wheat gluten (WG) to deamidated wheat gluten (DWG), the results as shown in Table 4 demonstrated that deamidation increased the susceptibility of the gluten to specific proteases, such that more protein became soluble. By addition of FLAVOURZYME™ with a specific protease, the release of glutamate was doubled due to deamidation.

Table 4

Hydrolysate	Protein Solubility %		Glutamate Content (mg/l)	
	WG	DWG	WG	DWG
SP446	18	54	0	0
SP387	35	44	0	0
SP446+FLAVOURZYME™	34	87	1000	2000

Example 12: Enzymatic deamidation and release of glutamate

Peptidoglutaminase II was produced by growing *Bacillus circulans* strain ATCC 21590 in shake flasks (400 ml) containing 200 ml of a medium composed of 1% polypeptone, 0.5% lactose, 0.025% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.005% $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.025% KH_2PO_4 , and 17% $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ (pH adjusted to 7.2), at 30°C for 20 hours with mixing at 270 rpm. The cells were harvested by centrifugation at 4000 rpm in 1 liter flasks. The cells were then frozen.

The purification of peptidoglutaminase II from *Bacillus circulans* was performed at room temperature. The frozen *Bacillus circulans* cells were thawed and suspended in Lysis buffer (50 mM Tris/HCl; 25% (w/v) sucrose; 1 mM EDTA, pH 8.0) until a homogeneous suspension was obtained - 100 g wet cells per liter of Lysis buffer. Lysozyme (10 mg/ml) and DNase I (Sigma DN-25, 10 mg/ml) were dissolved in Lysis buffer. Then 100 ml of lysozyme solution, 10 ml of 1.0 M MgCl_2 , and 1 ml of DNase I solution were added per liter of cell suspension. The enzymes were allowed to act for 1 hour.

The suspension was filtered through a Seitz depth filter plate and the filtrate was transferred to a 10 mM $\text{KH}_2\text{PO}_4/\text{NaOH}$, pH 8.0 (Buffer A) on a Sephadex G25 column (Pharmacia). The enzyme solution was applied to a SOURCE Q column (Pharmacia) equilibrated in Buffer A and eluted with a linear NaCl gradient (0 → 500 mM) in Buffer A. Fractions from the column were analysed for Peptidoglutaminase II activity as described below and fractions with activity were pooled. The absorbance of the pooled fractions at 280 nm was 1.78, thus the protein content was estimated to 1.8 mg/ml.

The purity of the protein in the peptidoglutaminase II pool was approximately 25% as judged from a SDS-PAGE gel. Thus, the preparation contained approximately 0.5 mg/ml of pure peptidoglutaminase II.

The peptidoglutaminase activity was determined by measuring the ammonia formed during hydrolysis of γ -carboxyamide of N-tert-Butoxycarbonyl-Gln-Pro (N-t-BOC-Gln-Pro; SIGMA No. B-4403) using the Boehringer-Mannheim kit for ammonia determination (Cat. No. 1112732). In this kit, ammonia was measured by determination of the consumption of NADH by glutamate dehydrogenase, and blanks without the addition of N-t-BOC-Gln-Pro were also applied in order to subtract the effect of other NADH consuming enzymes.

A total of 200 mg of wheat gluten protein was added to 9 ml of boiling water and after cooling, the pH was adjusted to 7.0. Then 250 μl of the peptidoglutaminase II

preparation (PEP) described above was added. The glutamate/aspartate specific protease (SP446) described in Example 11 was added in an amount of 0.04 AU/g protein, and FLAVOURZYME™ described in Example 11 was added in an amount of 20 LAPU/g protein.

Hydrolysis was allowed to proceed without pH adjustment for 18 hours at 50°C. Controls without the addition of peptidoglutaminase were also run. The hydrolysates were centrifuged and glutamate was measured as described in Example 11.

The DH of the wheat gluten protein was determined as described in Example 10.

The results as shown below in Table 5 demonstrated that hydrolysis with the peptidoglutaminase preparation increased the DH as well as the release of glutamate.

Table 5

Hydrolysis	DH %	Glutamate (mg/l)
Minus PEP	40	131
Plus PEP	43	171

Example 13: Flavor improvement of soy hydrolysates

The soy hydrolysates were prepared using an 8% soy meal protein concentration (1 or 0.2 liter) at 50°C for 18 hours with no pH adjustment with ALCALASE™ 2.4L (Novo Nordisk, Bagsværd, Denmark) and a solution of purified carboxypeptidase (approximately 40 CPDU/ml) prepared as described in Example 1. The dosages were 1200 mg of ALCALASE™ per liter or 1200 mg of ALCALASE™ and 5 ml of carboxypeptidase per liter.

The enzymes were then inactivated at 93°C for 15 minutes and analyzed for DH and glutamate as described in Examples 10 and 11, respectively. The pH was adjusted to 5 before maturation at 125°C for 30 minutes. All hydrolysates were centrifuged after maturation.

The soy bean meal hydrolysates produced were evaluated by a trained taste panel. The supernatants were diluted 5.3 times and presented twice to eleven judges in randomised order. The judges evaluated on a scale from 0 to 9 the following flavor attributes: Bitterness, palatability, bouillon, meat, chicken, smoke, and MSG.

The DH results and the mean scores for the different flavor attributes are shown in Table 6.

Table 6

Treatment	DH	bitterness	palatability	bouillon	meat	vegetable	chicken	smoke	MSG
Alcalase	17.3	4.45	1.68	1.95	1.14	1.86	1.82	2.77	1.41
Alcalase + CPD	33.0	2.77	2.18	2.59	1.41	2.23	2.36	3.14	1.86

The bitterness results showed that addition of carboxypeptidase to ALCALASE™ significantly reduced bitterness. With respect to overall palatability, improvement was seen by adding carboxypeptidase to ALCALASE™.

Bouillon, chicken, and possibly MSG flavors were also improved by addition of carboxypeptidase to ALCALASE™. Meat, smoke, and vegetable flavors were also improved by the addition of carboxypeptidase.

Deposit of Biological Materials

The following biological material has been deposited under the terms of the Budapest Treaty with the Agricultural Research Service Patent Culture Collection, Northern Regional Research Center, 1815 University Street, Peoria, Illinois, 61604, and given the following accession number:

Deposit	Accession Number	Date of Deposit
<i>E. coli</i> DH5a pEJG12	NRRL B-21616	August 28, 1996

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Blinkovsky, Alexander
Berka, Randy
Rey, Michael
Golightly, Elizabeth
Klotz, Alan
Mathisen, Thomas Erik
Dambmann, Claus
- (ii) TITLE OF THE INVENTION: Carboxypeptidases And Nucleic Acids
Encoding Same
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Novo Nordisk of North America, Inc.
 - (B) STREET: 405 Lexington Avenue
 - (C) CITY: New York
 - (D) STATE: NY
 - (E) COUNTRY: USA
 - (F) ZIP: 10174
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: to be assigned
 - (B) FILING DATE: 03-OCT-1997
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Lambiris, Elias J
 - (B) REGISTRATION NUMBER: 33,728
 - (C) REFERENCE/DOCKET NUMBER: 4990.200-US
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 212-867-0123
 - (B) TELEFAX: 212-878-9655
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1662 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: Genomic DNA
- (ix) FEATURE:
 - (A) NAME/KEY: Coding Sequence
 - (B) LOCATION: 1...1662
 - (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG CGT GGC TAC GAA TTT CTC TCA GTG CTA CCC TTG GTT GCA GCC AGT	48
Met Arg Gly Tyr Glu Phe Leu Ser Val Leu Pro Leu Val Ala Ala Ser	
1 5 10 15	
TGG GCC CTT CCA GGA AGT ACA CCG GCG TCC GTC GGT AGA AGA CAG CTA	96
Trp Ala Leu Pro Gly Ser Thr Pro Ala Ser Val Gly Arg Arg Gln Leu	
20 25 30	
CCC AAG AAC CCC ACC GGG GTC AAG ACT CTT ACA ACC GCA AAC AAT GTC	144
Pro Lys Asn Pro Thr Gly Val Lys Thr Leu Thr Thr Ala Asn Asn Val	
35 40 45	
ACC ATC CGG TAC AAG GAA CCC GGG GCA GAG GGC GTC TGC GAG ACT ACC	192
Thr Ile Arg Tyr Lys Glu Pro Gly Ala Glu Gly Val Cys Glu Thr Thr	
50 55 60	
CCG GGT GTC AAA TCC TAC TCT GGA TAT GTC GAC ACC TCT CCC GAG TCC	240
Pro Gly Val Lys Ser Tyr Ser Gly Tyr Val Asp Thr Ser Pro Glu Ser	
65 70 75 80	
CAT ACC TTC TTC TGG TTC TTC GAA GCC AGA CAT AAC CCA GAA ACT GCA	288
His Thr Phe Phe Trp Phe Phe Glu Ala Arg His Asn Pro Glu Thr Ala	
85 90 95	
CCT ATC ACA TTG TGG TTG AAT GGT GGC CCT GGA AGC GAT TCT TTG ATC	336
Pro Ile Thr Leu Trp Leu Asn Gly Gly Pro Gly Ser Asp Ser Leu Ile	
100 105 110	
GGT CTC TTC GAA GAG TTG GGC CCT TGC CAT GTC AAT TCG ACT TTT GAT	384
Gly Leu Phe Glu Glu Leu Gly Pro Cys His Val Asn Ser Thr Phe Asp	
115 120 125	
GAC TAC ATC AAC CCT CAC TCG TGG AAC GAG GTC TCC AAT TTA CTA TTC	432
Asp Tyr Ile Asn Pro His Ser Trp Asn Glu Val Ser Asn Leu Leu Phe	
130 135 140	
CTG TCC CAG CCA TTG GGA GTC GGC TTT TCA TAT AGT GAT ACG GTT GAT	480
Leu Ser Gln Pro Leu Gly Val Gly Phe Ser Tyr Ser Asp Thr Val Asp	
145 150 155 160	
GGG TCC ATT AAC CCT GTA ACT GGG GTC GTC GAA AAT TCG AGC TTT GCA	528
Gly Ser Ile Asn Pro Val Thr Gly Val Val Glu Asn Ser Ser Phe Ala	
165 170 175	
GGA GTT CAG GGC CGG TAC CCA ACC ATT GAT GCC ACT CTG ATC GAT ACT	576
Gly Val Gln Gly Arg Tyr Pro Thr Ile Asp Ala Thr Leu Ile Asp Thr	
180 185 190	
ACC AAT CTT GCC GCA GAG GCC GCT TGG GAG ATC CTG CAA GGA TTC CTT	624
Thr Asn Leu Ala Ala Glu Ala Ala Trp Glu Ile Leu Gln Gly Phe Leu	
195 200 205	
AGT GGA CTA CCT AGC TTG GAC TCT AGG GTG CAG TCT AAG GAC TTC AGT	672
Ser Gly Leu Pro Ser Leu Asp Ser Arg Val Gln Ser Lys Asp Phe Ser	
210 215 220	
CTA TGG ACG GAG AGC TAT GGA GGG CAC TAT GGT CCT GCA TTC TTC AAT	720
Leu Trp Thr Glu Ser Tyr Gly Gly His Tyr Gly Pro Ala Phe Phe Asn	
225 230 235 240	
CAT TTT TAC GAG CAG AAT GAG AGA ATT GCC AAC GGT AGT GTT AAT GGT	768
His Phe Tyr Glu Gln Asn Glu Arg Ile Ala Asn Gly Ser Val Asn Gly	
245 250 255	

GTT CAG CTT AAT TTC AAC TCT CTG GGA ATT ATT AAC GGC ATC ATC GAC Val Gln Leu Asn Phe Asn Ser Leu Gly Ile Ile Asn Gly Ile Ile Asp 260 265 270	816
GAG GCG ATC CAG GCC CCT TAC TAC CCT GAA TTC GCT GTG AAC AAT ACC Glu Ala Ile Gln Ala Pro Tyr Tyr Pro Glu Phe Ala Val Asn Asn Thr 275 280 285	864
TAC GGT ATC AAG GCT GTC AAC GAG ACC GTC TAC AAC TAC ATG AAG TTT Tyr Gly Ile Lys Ala Val Asn Glu Thr Val Tyr Asn Tyr Met Lys Phe 290 295 300	912
GCC AAC CAA ATG CCA AAT GGT TGC CAG GAT TTG ATT TCC ACC TGC AAA Ala Asn Gln Met Pro Asn Gly Cys Gln Asp Leu Ile Ser Thr Cys Lys 305 310 315 320	960
CAG ACA AAC CGC ACC GCA TTA GCT GAC TAC GCC CTC TGC GCC GAA GCC Gln Thr Asn Arg Thr Ala Leu Ala Asp Tyr Ala Leu Cys Ala Glu Ala 325 330 335	1008
ACC AAC ATG TGC AGG GAC AAT GTT GAG GGG CCA TAC TAC GCC TTT GCT Thr Asn Met Cys Arg Asp Asn Val Glu Gly Pro Tyr Tyr Ala Phe Ala 340 345 350	1056
GGT CGT GGT GTG TAT GAT ATT CGG CAT CCA TAT GAT GAC CCG ACT CCG Gly Arg Gly Val Tyr Asp Ile Arg His Pro Tyr Asp Asp Pro Thr Pro 355 360 365	1104
CCA AGT TAT TAC AAC AAA TTT CTG GCA AAG GAC TCT GTC ATG GAC GCT Pro Ser Tyr Tyr Asn Lys Phe Leu Ala Lys Asp Ser Val Met Asp Ala 370 375 380	1152
ATC GGC GTC AAC ATC AAC TAC ACC CAG TCC AAT AAT GAC GTC TAC TAC Ile Gly Val Asn Ile Asn Tyr Thr Gln Ser Asn Asn Asp Val Tyr Tyr 385 390 395 400	1200
GCT TTC CAG CAA ACA GGC GAC TTT GTC TGG CCC AAC TTC ATC GAA GAC Ala Phe Gln Gln Thr Gly Asp Phe Val Trp Pro Asn Phe Ile Glu Asp 405 410 415	1248
CTC GAG GAG ATC CTT GCT CTC CCC GTG CGT GTC TCC CTC ATC TAT GGC Leu Glu Glu Ile Leu Ala Leu Pro Val Arg Val Ser Leu Ile Tyr Gly 420 425 430	1296
GAC GCC GAT TAC ATC TGC AAC TGG TTC GGC GGT CAG GCC GTT TCC CTC Asp Ala Asp Tyr Ile Cys Asn Trp Phe Gly Gly Gln Ala Val Ser Leu 435 440 445	1344
GCT GCG AAC TAC TCC CAA GCC GCC CAG TTC CGA AGC GCA GGG TAC ACG Ala Ala Asn Tyr Ser Gln Ala Ala Gln Phe Arg Ser Ala Gly Tyr Thr 450 455 460	1392
CCC CTG AAA GTC AAC GGC GTC GAG TAT GGG GAA ACT CGC GAG TAT GGT Pro Leu Lys Val Asn Gly Val Glu Tyr Gly Glu Thr Arg Glu Tyr Gly 465 470 475 480	1440
AAT TTC TCC TTC ACT CGC GTC TAT GAG GCA GGC CAT GAA GTC CCA TAC Asn Phe Ser Phe Thr Arg Val Tyr Glu Ala Gly His Glu Val Pro Tyr 485 490 495	1488
TAC CAG CCC ATC GCC TCC CTG CAA TTG TTT AAC CGG ACT ATC TTC GGT Tyr Gln Pro Ile Ala Ser Leu Gln Leu Phe Asn Arg Thr Ile Phe Gly 500 505 510	1536
TGG GAT ATC GCA GAG GGC CAG AAG AAG ATC TGG CCC AGC TAC AAG ACG Trp Asp Ile Ala Glu Gly Gln Lys Lys Ile Trp Pro Ser Tyr Lys Thr 515 520 525	1584

AAT GGA ACG GCT ACA GCT ACG CAT ACA CAG TCG TCC GTG CCG CTG CCT	1632
Asn Gly Thr Ala Thr Ala Thr His Thr Gln Ser Ser Val Pro Leu Pro	
530 535 540	
ACG GCT ACC AGC ATG TCC AGT GTT GGT ATG	62 1662
Thr Ala Thr Ser Met Ser Ser Val Gly Met	
545 550	

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 554 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Arg	Gly	Tyr	Glu	Phe	Leu	Ser	Val	Leu	Pro	Leu	Val	Ala	Ala	Ser	1	5	10	15
Trp	Ala	Leu	Pro	Gly	Ser	Thr	Pro	Ala	Ser	Val	Gly	Arg	Arg	Gln	Leu	20	25	30	
Pro	Lys	Asn	Pro	Thr	Gly	Val	Lys	Thr	Leu	Thr	Thr	Ala	Asn	Asn	Val	35	40	45	
Thr	Ile	Arg	Tyr	Lys	Glu	Pro	Gly	Ala	Glu	Gly	Val	Cys	Glu	Thr	Thr	50	55	60	
Pro	Gly	Val	Lys	Ser	Tyr	Ser	Gly	Tyr	Val	Asp	Thr	Ser	Pro	Glu	Ser	65	70	75	80
His	Thr	Phe	Phe	Trp	Phe	Phe	Glu	Ala	Arg	His	Asn	Pro	Glu	Thr	Ala	85	90	95	
Pro	Ile	Thr	Leu	Trp	Leu	Asn	Gly	Gly	Pro	Gly	Ser	Asp	Ser	Leu	Ile	100	105	110	
Gly	Leu	Phe	Glu	Glu	Leu	Gly	Pro	Cys	His	Val	Asn	Ser	Thr	Phe	Asp	115	120	125	
Asp	Tyr	Ile	Asn	Pro	His	Ser	Trp	Asn	Glu	Val	Ser	Asn	Leu	Leu	Phe	130	135	140	
Leu	Ser	Gln	Pro	Leu	Gly	Val	Gly	Phe	Ser	Tyr	Ser	Asp	Thr	Val	Asp	145	150	155	160
Gly	Ser	Ile	Asn	Pro	Val	Thr	Gly	Val	Val	Glu	Asn	Ser	Ser	Phe	Ala	165	170	175	
Gly	Val	Gln	Gly	Arg	Tyr	Pro	Thr	Ile	Asp	Ala	Thr	Leu	Ile	Asp	Thr	180	185	190	
Thr	Asn	Leu	Ala	Ala	Glu	Ala	Ala	Trp	Glu	Ile	Leu	Gln	Gly	Phe	Leu	195	200	205	
Ser	Gly	Leu	Pro	Ser	Leu	Asp	Ser	Arg	Val	Gln	Ser	Lys	Asp	Phe	Ser	210	215	220	
Leu	Trp	Thr	Glu	Ser	Tyr	Gly	Gly	His	Tyr	Gly	Pro	Ala	Phe	Phe	Asn	225	230	235	240

His	Phe	Tyr	Glu	Gln	Asn	Glu	Arg	Ile	Ala	Asn	Gly	Ser	Val	Asn	Gly	
				245					250					255		
Val	Gln	Leu	Asn	Phe	Asn	Ser	Leu	Gly	Ile	Ile	Asn	Gly	Ile	Ile	Asp	
			260					265					270			
Glu	Ala	Ile	Gln	Ala	Pro	Tyr	Tyr	Pro	Glu	Phe	Ala	Val	Asn	Asn	Thr	
		275					280					285				
Tyr	Gly	Ile	Lys	Ala	Val	Asn	Glu	Thr	Val	Tyr	Asn	Tyr	Met	Lys	Phe	
	290					295					300					
Ala	Asn	Gln	Met	Pro	Asn	Gly	Cys	Gln	Asp	Leu	Ile	Ser	Thr	Cys	Lys	
305					310					315					320	
Gln	Thr	Asn	Arg	Thr	Ala	Leu	Ala	Asp	Tyr	Ala	Leu	Cys	Ala	Glu	Ala	
			325					330						335		
Thr	Asn	Met	Cys	Arg	Asp	Asn	Val	Glu	Gly	Pro	Tyr	Tyr	Ala	Phe	Ala	
		340						345					350			
Gly	Arg	Gly	Val	Tyr	Asp	Ile	Arg	His	Pro	Tyr	Asp	Asp	Pro	Thr	Pro	
		355					360					365				
Pro	Ser	Tyr	Tyr	Asn	Lys	Phe	Leu	Ala	Lys	Asp	Ser	Val	Met	Asp	Ala	
	370					375					380					
Ile	Gly	Val	Asn	Ile	Asn	Tyr	Thr	Gln	Ser	Asn	Asn	Asp	Val	Tyr	Tyr	
385					390					395					400	
Ala	Phe	Gln	Gln	Thr	Gly	Asp	Phe	Val	Trp	Pro	Asn	Phe	Ile	Glu	Asp	
			405					410						415		
Leu	Glu	Glu	Ile	Leu	Ala	Leu	Pro	Val	Arg	Val	Ser	Leu	Ile	Tyr	Gly	
			420					425					430			
Asp	Ala	Asp	Tyr	Ile	Cys	Asn	Trp	Phe	Gly	Gly	Gln	Ala	Val	Ser	Leu	
		435					440					445				
Ala	Ala	Asn	Tyr	Ser	Gln	Ala	Ala	Gln	Phe	Arg	Ser	Ala	Gly	Tyr	Thr	
	450					455					460					
Pro	Leu	Lys	Val	Asn	Gly	Val	Glu	Tyr	Gly	Glu	Thr	Arg	Glu	Tyr	Gly	
465					470					475					480	
Asn	Phe	Ser	Phe	Thr	Arg	Val	Tyr	Glu	Ala	Gly	His	Glu	Val	Pro	Tyr	
			485					490						495		
Tyr	Gln	Pro	Ile	Ala	Ser	Leu	Gln	Leu	Phe	Asn	Arg	Thr	Ile	Phe	Gly	
		500						505					510			
Trp	Asp	Ile	Ala	Glu	Gly	Gln	Lys	Lys	Ile	Trp	Pro	Ser	Tyr	Lys	Thr	
	515						520					525				
Asn	Gly	Thr	Ala	Thr	Ala	Thr	His	Thr	Gln	Ser	Ser	Val	Pro	Leu	Pro	
	530					535					540					
Thr	Ala	Thr	Ser	Met	Ser	Ser	Val	Gly	Met							
545					550											

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Xaa Tyr Gly Gly His Tyr Gly Pro Ala Phe Phe Asn His Phe Tyr Glu
1 5 10 15
Gln Asn Glu Arg
20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asp Ala Ile Gly Val Asn Ile Xaa Tyr Thr Gln Xaa Asn Asn Asp Val
1 5 10 15
Tyr Tyr Ala

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Asp Ala Ile Gly Val Asn Ile Asn Tyr Thr Gln Ser Asn Asn Asp Val
1 5 10 15
Tyr Tyr Ala Phe Gln Gln Thr Gly Asp Phe Val Trp Pro Asn Phe Ile
20 25 30
Glu Asp Leu
35

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Xaa Cys Arg Asp Asn Val Glu Gly Pro Xaa Tyr Ala Phe Ala Gly Arg
1 5 10 15

Gly Val Tyr Asp Ile Arg His Pro Tyr Asp Pro Asp Thr
 20 25

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TAYGGNGGCA YTAYGGCCNG

20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATRAARTTGG CCAACRAART C

21

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 423 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Phe	Val	Lys	Asn	Ser	Gly	Ile	Cys	Glu	Thr	Thr	Pro	Gly	Val	Asn	Gln
1				5					10					15	
Tyr	Ser	Gly	Tyr	Leu	Ser	Val	Gly	Ser	Asn	Met	Asn	Met	Trp	Phe	Trp
		20						25					30		
Phe	Phe	Glu	Ala	Arg	Asn	Asn	Pro	Gln	Gln	Ala	Pro	Leu	Ala	Ala	Trp
		35					40					45			
Phe	Asn	Gly	Gly	Pro	Gly	Cys	Ser	Ser	Met	Ile	Gly	Leu	Phe	Gln	Glu
	50					55					60				
Asn	Gly	Pro	Cys	His	Phe	Val	Asn	Gly	Asp	Ser	Thr	Pro	Ser	Leu	Asn
65					70					75				80	
Glu	Asn	Ser	Trp	Asn	Asn	Tyr	Ala	Asn	Met	Ile	Tyr	Ile	Asp	Gln	Pro
			85						90					95	
Ile	Gly	Val	Gly	Phe	Ser	Tyr	Gly	Thr	Asp	Asp	Val	Thr	Ser	Thr	Val
		100						105					110		
Thr	Ala	Ala	Pro	Tyr	Val	Trp	Asn	Leu	Leu	Gln	Ala	Phe	Tyr	Ala	Gln
		115					120					125			
Arg	Pro	Glu	Tyr	Glu	Ser	Arg	Asp	Phe	Ala	Ile	Phe	Thr	Glu	Ser	Tyr
		130				135					140				
Gly	Gly	His	Tyr	Gly	Pro	Glu	Phe	Ala	Ser	Tyr	Ile	Glu	Gln	Gln	Asn
145					150					155				160	
Ala	Ala	Ile	Lys	Ala	Gly	Ser	Val	Thr	Gly	Gln	Asn	Val	Asn	Ile	Val
			165						170					175	
Ala	Leu	Gly	Val	Asn	Asn	Gly	Trp	Ile	Asp	Ser	Thr	Ile	Gln	Glu	Lys
		180					185						190		

Ala	Tyr	Ile	Asp	Phe	Ser	Tyr	Asn	Asn	Ser	Tyr	Gln	Gln	Ile	Ile	Asp
		195					200				205				
Ser	Ser	Thr	Arg	Asp	Ser	Leu	Leu	Asp	Ala	Tyr	Asn	Asn	Gln	Cys	Leu
		210				215					220				
Pro	Ala	Leu	Gln	Gln	Cys	Ser	Gln	Ser	Gly	Ser	Thr	Ser	Asp	Cys	Thr
		225			230					235					240
Asn	Ala	Asp	Ser	Val	Cys	Tyr	Gln	Asn	Ile	Glu	Gly	Pro	Ile	Ser	Ser
				245					250					255	
Ser	Gly	Asp	Phe	Asp	Val	Tyr	Asp	Ile	Arg	Glu	Pro	Ser	Asn	Asp	Pro
			260					265					270		
Tyr	Pro	Pro	Lys	Thr	Tyr	Ser	Thr	Tyr	Leu	Ser	Asp	Pro	Thr	Val	Val
			275				280					285			
Lys	Ala	Ile	Gly	Ala	Arg	Thr	Asn	Tyr	Gln	Glu	Cys	Pro	Asn	Gly	Pro
		290				295					300				
Tyr	Asn	Lys	Phe	Ala	Ser	Thr	Gly	Asp	Asn	Pro	Arg	Ser	Phe	Leu	Ser
		305			310					315					320
Thr	Leu	Ser	Ser	Val	Val	Gln	Ser	Gly	Ile	Asn	Val	Leu	Val	Trp	Ala
				325					330					335	
Gly	Asp	Ala	Asp	Trp	Ile	Cys	Asn	Trp	Leu	Gly	Asn	Tyr	Glu	Val	Ala
			340					345				350			
Asn	Ala	Val	Asp	Phe	Pro	Gly	Asn	Ala	Gln	Phe	Ser	Ala	Leu	Asp	Leu
		355					360					365			
Ala	Pro	Tyr	Thr	Val	Asn	Gly	Val	Glu	Lys	Gly	Gln	Phe	Lys	Thr	Val
		370			375						380				
Asp	Asn	Phe	Ser	Phe	Leu	Lys	Val	Tyr	Gly	Ala	Gly	His	Glu	Val	Pro
		385			390					395					400
Tyr	Tyr	Gln	Pro	Asp	Thr	Ala	Leu	Gln	Ala	Phe	Lys	Gln	Ile	Ile	Gln
				405				410						415	
Lys	Lys	Pro	Ile	Ser	Ser	Thr									
			420												

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 481 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ser	Thr	Lys	Asn	Tyr	Arg	Phe	Leu	Asn	Glu	Lys	Thr	Lys	Ala	Asn	Leu
1				5					10					15	
Val	His	His	Leu	Pro	Asp	Val	Pro	Tyr	Asp	Ile	Gly	Glu	Met	Tyr	Ser
			20					25					30		
Gly	Leu	Met	Pro	Ile	Asp	Met	His	Asn	Glu	Ser	Arg	Ala	Leu	Phe	Tyr
		35				40					45				
Ile	Phe	Gln	Pro	Thr	Ile	Gly	Glu	Pro	Val	Asp	Glu	Val	Thr	Ile	Trp
		50			55					60					
Met	Asn	Gly	Gly	Pro	Gly	Cys	Ser	Ser	Met	Glu	Ser	Phe	Leu	Gln	Glu
		65			70				75					80	
Thr	Gly	Arg	Phe	Leu	Trp	Gln	Pro	Gly	Thr	Tyr	Ala	Pro	Val	Glu	Asn
			85					90					95		
Pro	Tyr	Ser	Trp	Val	Val	Leu	Thr	Asn	Val	Leu	Trp	Val	Asp	Gln	Pro
		100						105					110		
Val	Gly	Thr	Gly	Tyr	Ser	Ile	Gly	Thr	Pro	Thr	Ala	Thr	Ser	Gln	Glu
		115				120					125				
Glu	Thr	Ala	Gln	Asp	Phe	Val	Lys	Phe	Phe	Lys	Asn	Phe	Gln	Lys	Thr
		130				135					140				
Tyr	Gly	Ile	Lys	Asn	Phe	Lys	Ile	Tyr	Val	Thr	Gly	Glu	Ser	Tyr	Ala
		145			150					155				160	
Gly	Arg	Tyr	Val	Pro	Tyr	Ile	Ser	Ala	Ala	Met	Leu	Asp	Glu	Lys	Asp
			165					170						175	
Lys	Glu	Tyr	Phe	Asp	Leu	Gln	Gly	Ala	Leu	Ala	Tyr	Asp	Pro	Cys	Ile
			180					185					190		

Gly	Gln	Phe	Asp	Tyr	Val	Gln	Glu	Glu	Ile	Pro	Val	Val	Pro	Phe	Val
		195					200				205				
Lys	Glu	Asn	Ala	Asn	Leu	Phe	Asn	Phe	Asn	Glu	Thr	Phe	Met	Ala	Glu
		210				215					220				
Leu	Glu	His	Leu	His	Lys	Ser	Cys	Gly	Tyr	Ala	Asp	Phe	Ile	Asp	Lys
		225			230					235					240
Tyr	Leu	Thr	Phe	Pro	Pro	Pro	Lys	Glu	Gln	Pro	Pro	Leu	Phe	Phe	Asn
			245						250					255	
Tyr	Thr	Ser	Met	Ala	Asn	Glu	Asp	Val	Phe	Asp	Met	Val	Tyr	Asn	Glu
			260					265					270		
Val	Phe	Lys	Ile	Asn	Pro	Cys	Phe	Asp	Leu	Tyr	Glu	Val	Asn	Leu	Met
		275					280					285			
Cys	Pro	Leu	Gln	Trp	Asp	Val	Leu	Ala	Phe	Pro	Thr	Ser	Leu	Val	Tyr
		290				295					300				
Gln	Pro	Ala	Gly	Ala	Thr	Val	Tyr	Phe	Asp	Arg	Ala	Asp	Val	Lys	Lys
		305			310					315					320
Ala	Leu	His	Ala	Pro	Asn	Val	Thr	Trp	Ala	Glu	Cys	Ser	Asn	Asn	Pro
			325						330					335	
Val	Phe	Val	Gly	Ser	Ser	Gly	Pro	Glu	Gln	Glu	Gly	Asp	Thr	Ser	
		340				345						350			
Ala	Asn	Pro	Ile	Glu	His	Val	Leu	Pro	Gln	Val	Ile	Glu	Ala	Thr	Asn
		355				360						365			
Arg	Val	Leu	Ile	Ser	Asn	Gly	Asp	Phe	Asp	Met	Val	Ile	Leu	Thr	Asn
		370				375					380				
Gly	Thr	Leu	Leu	Ala	Ile	Gln	Asn	Met	Thr	Trp	Asn	Gly	His	Leu	Gly
		385			390					395					400
Phe	Gln	Lys	Lys	Pro	Ser	Ala	Pro	Ile	Asp	Ile	Lys	Ile	Pro	Asp	Leu
			405						410					415	
Gln	Tyr	Lys	Glu	Val	Phe	Ala	Glu	Asn	Gly	Ala	Ser	Ser	Leu	Asp	Gly
		420						425					430		
Ala	Gln	Gly	Ile	Met	Gly	Val	Gln	His	Tyr	Glu	Arg	Gly	Leu	Met	Lys
		435					440					445			
Ala	Gln	Thr	Tyr	Gln	Ser	Gly	His	Met	Gln	Pro	Gln	Tyr	Gln	Pro	Arg
		450				455					460				
Val	Ala	Tyr	Arg	His	Leu	Glu	Trp	Leu	Leu	Lys	Arg	Thr	Asp	Glu	Leu
		465			470					475					480
Gln															

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 523 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met	Arg	Ile	Thr	Ser	Ala	Ile	Ala	Ser	Leu	Leu	Val	Gly	Thr	Ala
1				5					10				15	
Thr	Ser	Leu	Gln	Asn	Pro	His	Arg	Arg	Ala	Val	Pro	Ala	Pro	Leu
			20					25				30		Thr
His	Arg	Ser	Val	Ala	Ser	Arg	Ala	Val	Pro	Val	Glu	Arg	Arg	Ser
		35				40					45			Asn
Asp	Phe	Glu	Tyr	Leu	Thr	Asn	Lys	Thr	Ala	Arg	Phe	Leu	Val	Asn
	50					55				60				Gly
Thr	Ser	Ile	Pro	Glu	Val	Asp	Phe	Asp	Val	Gly	Glu	Ser	Tyr	Ala
	65				70					75				80
Leu	Leu	Pro	Asn	Thr	Pro	Thr	Gly	Asn	Ser	Ser	Leu	Phe	Phe	Trp
				85				90					95	Phe
Phe	Pro	Ser	Gln	Asn	Pro	Asp	Ala	Ser	Asp	Glu	Ile	Thr	Ile	Trp
		100						105					110	Leu
Asn	Gly	Gly	Pro	Gly	Cys	Ser	Ser	Leu	Asp	Gly	Leu	Leu	Gln	Glu
		115					120					125		Asn
Gly	Pro	Phe	Leu	Trp	Gln	Pro	Gly	Thr	Tyr	Lys	Pro	Val	Pro	Asn
	130					135					140			Pro

Tyr	Ser	Trp	Thr	Asn	Leu	Thr	Asn	Val	Val	Tyr	Ile	Asp	Gln	Pro	Ala	
145					150					155					160	
Gly	Thr	Gly	Phe	Ser	Pro	Gly	Pro	Ser	Thr	Val	Asn	Asp	Glu	Glu	Asp	
				165					170						175	
Val	Ala	Ala	Gln	Phe	Asn	Ser	Trp	Phe	Lys	His	Phe	Val	Asp	Thr	Phe	
			180					185					190			
Asp	Leu	His	Gly	Arg	Lys	Val	Tyr	Ile	Thr	Gly	Glu	Ser	Tyr	Ala	Gly	
		195					200					205				
Met	Tyr	Val	Pro	Tyr	Ile	Ala	Asp	Ala	Met	Leu	Asn	Glu	Glu	Asp	Thr	
	210					215					220					
Thr	Tyr	Phe	Asn	Leu	Lys	Gly	Ile	Gln	Ile	Asn	Asp	Pro	Ser	Ile	Asn	
225					230					235					240	
Ser	Asp	Ser	Val	Met	Tyr	Ser	Pro	Ala	Val	Arg	His	Leu	Asn	His		
				245				250					255			
Tyr	Asn	Asn	Ile	Phe	Arg	Leu	Asn	Ser	Thr	Phe	Leu	Ser	Tyr	Ile	Asn	
			260					265					270			
Gly	Lys	Ala	Asp	Lys	Cys	Gly	Tyr	Asn	Ala	Phe	Leu	Asp	Lys	Ala	Ile	
		275					280					285				
Thr	Tyr	Pro	Pro	Pro	Thr	Pro	Phe	Pro	Thr	Ala	Pro	Glu	Ile	Thr	Glu	
	290					295					300					
Asp	Cys	Gln	Val	Trp	Asp	Glu	Val	Val	Met	Ala	Ala	Tyr	Asp	Ile	Asn	
305					310					315					320	
Pro	Cys	Phe	Asn	Tyr	Tyr	His	Leu	Ile	Asp	Phe	Cys	Pro	Tyr	Leu	Trp	
			325						330					335		
Asp	Val	Leu	Gly	Phe	Pro	Ser	Leu	Gly	Phe	Gly	Pro	Asp	Asn	Tyr	Phe	
			340					345					350			
Asn	Arg	Ser	Asp	Val	Gln	Lys	Ile	Leu	His	Val	Pro	Pro	Thr	Asp	Tyr	
		355					360					365				
Ser	Val	Cys	Ser	Glu	Thr	Val	Ile	Phe	Ala	Asn	Gly	Asp	Gly	Ser	Asp	
	370					375					380					
Pro	Ser	Ser	Trp	Gly	Pro	Leu	Pro	Ser	Val	Ile	Glu	Arg	Thr	Asn	Asn	
385					390					395					400	
Thr	Ile	Ile	Gly	His	Gly	Trp	Leu	Asp	Tyr	Leu	Leu	Phe	Leu	Asn	Gly	
				405					410					415		
Ser	Leu	Ala	Thr	Ile	Gln	Asn	Met	Thr	Trp	Asn	Gly	Lys	Gln	Gly	Phe	
			420					425					430			
Gln	Ser	Pro	Pro	Val	Glu	Pro	Leu	Phe	Val	Pro	Tyr	His	Tyr	Gly	Leu	
		435					440					445				
Ala	Glu	Leu	Tyr	Trp	Gly	Asp	Glu	Pro	Asp	Pro	Tyr	Asn	Leu	Asp	Ala	
						455					460					
Gly	Ala	Gly	Tyr	Leu	Gly	Thr	Ala	His	Thr	Glu	Arg	Gly	Leu	Thr	Phe	
465					470					475					480	
Ser	Ser	Val	Tyr	Leu	Ser	Gly	His	Glu	Ile	Pro	Gln	Tyr	Val	Pro	Gly	
				485					490					495		
Ala	Leu	Thr	Ala	Ser	Trp	Ser	Ser	Cys	Leu	Val	Glu	Leu	Ile	Val	Phe	
			500					505					510			
Pro	Arg	Arg	Gly	Thr	Thr	Pro	Leu	Asn	Phe	Ser						
		515					520									

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 530 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met	Leu	Phe	Arg	Ser	Leu	Leu	Ser	Thr	Ala	Val	Leu	Ala	Val	Ser	Leu	
1				5					10					15		
Cys	Thr	Asp	Asn	Ala	Ser	Ala	Ala	Lys	His	Gly	Arg	Phe	Gly	Gln	Lys	
			20					25					30			
Ala	Arg	Asp	Ala	Met	Asn	Ile	Ala	Asn	Gly	Ser	Ala	Asn	Ala	Val	Lys	
		35					40					45				

His	Ser	Leu	Lys	Ile	Pro	Val	Glu	Asp	Tyr	Gln	Phe	Leu	Asn	Asn	Lys
	50					55					60				
Thr	Lys	Pro	Tyr	Arg	Val	Glu	Ser	Leu	Pro	Asp	Val	His	Phe	Asp	Leu
65					70					75					80
Gly	Glu	Met	Tyr	Ser	Gly	Leu	Val	Pro	Ile	Glu	Lys	Gly	Asn	Val	Ser
				85					90					95	
Arg	Ser	Leu	Phe	Phe	Val	Phe	Gln	Pro	Thr	Ile	Gly	Glu	Pro	Val	Asp
			100					105					110		
Glu	Thr	Thr	Ile	Trp	Leu	Asn	Gly	Gly	Pro	Gly	Cys	Ser	Ser	Leu	Glu
		115					120					125			
Ala	Leu	Ser	Pro	Gly	Glu	Cys	Arg	Phe	Val	Trp	Gln	Pro	Gly	Thr	Tyr
	130						135				140				
Gln	Pro	Val	Glu	Asn	Pro	Tyr	Ser	Trp	Val	Asn	Leu	Thr	Asn	Val	Leu
145					150					155					160
Trp	Val	Asp	Gln	Pro	Val	Gly	Thr	Gly	Phe	Ser	Leu	Gly	Val	Pro	Thr
				165					170					175	
Ala	Thr	Ser	Glu	Glu	Glu	Ile	Ala	Glu	Asp	Phe	Val	Lys	Phe	Phe	Lys
			180					185					190		
Asn	Trp	Gln	Gln	Ile	Phe	Gly	Ile	Lys	Asn	Phe	Lys	Ile	Tyr	Val	Thr
		195					200					205			
Gly	Glu	Ser	Tyr	Ala	Gly	Arg	Tyr	Val	Pro	Tyr	Ile	Ser	Ala	Ala	Phe
	210					215					220				
Leu	Asp	Gln	Asn	Asp	Thr	Glu	His	Phe	Asn	Leu	Lys	Gly	Ala	Leu	Ala
225					230					235					240
Tyr	Asp	Pro	Cys	Ile	Gly	Gln	Phe	Asp	Tyr	Val	Gln	Glu	Glu	Ala	Pro
				245					250					255	
Val	Val	Pro	Phe	Val	Gln	Lys	Asn	Asn	Ala	Leu	Phe	Asn	Phe	Asn	Ala
			260					265					270		
Ser	Phe	Leu	Ala	Glu	Leu	Glu	Ser	Ile	His	Glu	Gln	Cys	Gly	Tyr	Lys
		275					280					285			
Asp	Phe	Ile	Asp	Gln	Tyr	Leu	Val	Phe	Pro	Ala	Ser	Gly	Val	Gln	Pro
	290					295					300				
Pro	Lys	Ala	Met	Asn	Trp	Ser	Asp	Pro	Thr	Cys	Asp	Val	Tyr	Asp	Ile
305					310					315					320
Val	Asn	Asn	Ala	Val	Leu	Asp	Pro	Asn	Pro	Cys	Phe	Asn	Pro	Tyr	Glu
				325					330					335	
Ile	Asn	Glu	Met	Cys	Pro	Ile	Leu	Trp	Asp	Val	Leu	Gly	Phe	Pro	Thr
			340					345					350		
Glu	Val	Asp	Tyr	Leu	Pro	Ala	Ala	Pro	Ala	Ser	Thr	Leu	Thr	Ala	Leu
		355						360					365		
Ile	Lys	Arg	Ala	Met	His	Ala	Pro	Asn	Ile	Thr	Trp	Ser	Glu	Cys	Ser
	370					375					380				
Val	Glu	Ser	Val	Phe	Val	Gly	Gly	Asp	Gly	Gly	Pro	Glu	Gln	Glu	Gly
385					390					395					400
Asp	Tyr	Ser	Ala	Asn	Pro	Ile	Glu	His	Val	Leu	Pro	Gln	Val	Ile	Glu
				405					410					415	
Gly	Thr	Asn	Arg	Val	Leu	Ile	Gly	Asn	Gly	Asp	Tyr	Asp	Met	Val	Ile
			420					425					430		
Leu	Thr	Asn	Gly	Thr	Leu	Leu	Ser	Ile	Gln	Asn	Met	Thr	Trp	Asn	Gly
		435					440					445			
Lys	Leu	Gly	Phe	Asp	Thr	Ala	Pro	Ser	Thr	Pro	Ile	Asn	Ile	Asp	Ile
	450					455					460				
Pro	Asp	Leu	Met	Tyr	Asn	Glu	Val	Phe	Ile	Glu	Asn	Gly	Tyr	Asp	Pro
465					470					475					480
Gln	Gly	Gly	Gln	Gly	Val	Met	Gly	Ile	Gln	His	Tyr	Glu	Arg	Gly	Leu
				485					490					495	
Met	Trp	Ala	Glu	Thr	Phe	Gln	Ser	Gly	His	Met	Gln	Pro	Gln	Phe	Gln
			500					505					510		
Pro	Arg	Val	Ser	Tyr	Arg	His	Leu	Glu	Trp	Leu	Leu	Gly	Arg	Arg	Asp
		515					520					525			
Thr	Leu														
	530														

Claims

What is claimed is:

- 5 1. An isolated polypeptide having carboxypeptidase activity, selected from the group consisting of:
 - (a) a polypeptide comprising an amino acid sequence which has at least 50% identity with the amino acid sequence of SEQ ID NO:2;
 - (b) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under
10 medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) its complementary strand, or (iii) a subsequence thereof;
 - (c) a polypeptide having (i) optimal activity in the range of about pH 3.0 to about pH 7.5 at 25°C; (ii) optimal activity in the range of about 55°C to about 60°C at pH 4; (iii) a residual activity of at least about 65.5% after 30 minutes at pH 4.0 and 60°C; and (iv) a
15 capability to hydrolyze X from N-CBZ-Ala-X wherein N-CBZ is N-carbobenzoxy and X is any amino acid;
 - (d) an allelic variant of (a) or (b); and
 - (e) a fragment of (a), (b), or (d), wherein the fragment retains carboxypeptidase activity.
- 20 2. The polypeptide of claim 1, which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) its complementary strand, or (iii) a subsequence thereof.
- 25 3. The polypeptide of claim 2, which is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with (i) the nucleic acid sequence of SEQ ID NO:1, (ii) its complementary strand, or (iii) a subsequence thereof.
4. The polypeptide of claim 3, which is obtained from a strain of *Aspergillus* or a
30 synonym or teleomorph thereof.

5. The polypeptide of claim 4, which is obtained from a strain of *Aspergillus oryzae* or a synonym or teleomorph thereof.

6. The polypeptide of claim 1, which has (i) optimal activity in the range of about pH 3.0 to about pH 7.5 at 25°C; (ii) optimal activity in the range of about 55°C to about 60°C at pH 4; (iii) a residual activity of at least about 65.5% after 30 minutes at pH 4.0 and 60°C; and (iv) a capability to hydrolyze X from N-CBZ-Ala-X wherein N-CBZ is N-carbobenzoxy and X is any amino acid.

7. The polypeptide of claim 6, which hydrolyzes N-CBZ-Ala-X wherein X is selected from the group consisting of Ile, Glu, Lys, Arg, Asp, Asn, Phe, and Tyr.

8. The polypeptide of claim 6, which is obtained from a strain of *Aspergillus* or a synonym or teleomorph thereof.

9. The polypeptide of claim 8, which is obtained from *Aspergillus oryzae* or a synonym or teleomorph thereof.

10. The polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2 or an allelic variant or fragment thereof which retains carboxypeptidase activity.

11. The polypeptide of claim 10, comprising the amino acid sequence of SEQ ID NO:2.

12. The polypeptide of claim 11, consisting of the amino acid sequence of SEQ ID NO:2.

13. A polypeptide having carboxypeptidase activity encoded by the nucleic acid sequence contained in plasmid pEJG12 contained in *E. coli*, NRRL B-21616.

14. An isolated nucleic acid sequence encoding the polypeptide of claim 1.

15. A nucleic acid construct comprising the nucleic acid sequence of claim 14 operably linked to one or more control sequences which direct the expression of the polypeptide in a suitable expression host.
- 5 16. A recombinant expression vector comprising the nucleic acid construct of claim 15, a promoter, and transcriptional and translational stop signals.
17. A recombinant host cell comprising the nucleic acid construct of claim 15.
- 10 18. A method for producing the polypeptide of claim 1 comprising (a) cultivating a strain, which in its wild-type form produces the polypeptide, to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide.
19. A method for producing the polypeptide of claim 1 comprising (a) cultivating a host
15 cell comprising a nucleic acid construct comprising a nucleic acid sequence encoding the polypeptide under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.
20. A method for producing a mutant of a cell, which comprises disrupting or deleting
20 a nucleic acid sequence encoding the polypeptide of claim 1 or a control sequence thereof, which results in the mutant producing less of the polypeptide than the cell.
21. The mutant produced by the method of claim 20.
- 25 22. A method for producing a heterologous polypeptide comprising (a) culturing the mutant of claim 21 under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.
23. A method of producing a hydrolysate from a proteinaceous substrate which comprises
30 subjecting the substrate to a polypeptide of claim 1 and an endopeptidase.
24. A protein hydrolysate produced by the method of claim 23.

25. A food product comprising the protein hydrolysate of claim 24.

26. A method of obtaining from a proteinaceous substrate a hydrolysate enriched in free glutamic acid and/or peptide bound glutamic acid residues, comprising subjecting the
5 substrate to a deamidation process and a polypeptide of claim 1.

27. The method of claim 26, further comprising subjecting the substrate to one or more unspecific acting endo- and/or exo-peptidase enzymes.

10 28. A protein hydrolysate obtained by the method of claim 27.

29. A food product comprising the hydrolysate of claim 28.

Abstract

The present invention relates to polypeptides having carboxypeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to
5 nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to methods of obtaining protein hydrolysates useful as flavor improving agents.

Fig. 1. pH-Dependence of the hydrolysis of CBZ-ALa-Ile catalyzed by the carboxypeptidase (25°C, 50 mM acetate buffer and 50 mM citric acid/KH₂PO₄ buffer at pH 2.9 and 3.3)





Fig. 2. Temperature optimum of hydrolysis of CBZ-Ala-Ile (1.5 mM) by the carboxypeptidase (50 mM acetic buffer, pH 4.0)



ATCGGTGGCTACGAATTTCTCTCAGTGCTACCCCTTGGTTGCACCCAGTTGGGCCCTTCCAGGAAGTACACCCGGTCCGTCCGT 95
MRGYBFLSVLPLVAASWALPGSTPASVGRRL
 ACCCAAGAACCCACCCGGTCAAGACTCTTACACCCCAACAATGTACCATCCGTACAAGGAACCCGGCCAGAGGCCGT 190
 PKNPTGVKTLTTANNVTIRYKEPGAEGVCE
 CCCCCGGTGTCAATCTCTCTGGATATGTGACACCTCTCCCGAGTCCCATACCTTCTTCTGGTCTTGAAGCCAGACATA 285
 TPGVKSYSYGYVDTSPESTFFWFPEARHNPE
 CCACCTATCACATTGTGGTGAATGGTCCCTCGAAGCGATTCTTGATCGGTCTTTCGAAGAGTTCCGCCCTTCCCATGTC 380
 APITLWLNNGPGSDSLIGLFEELGPCHVNSTF
 TGATGACTACATCAACCTCACTCGTGAAGCGGTCTCCAATTTACTATTCTGTCCAGCCATTGGAGTCCGCTTTTCATA 475
 DDYINPHSWNEVSNLLFLSQPLGVGFSYSDT
 TTGATCGGTCCATTAAACCTGTAACTCCGGTGGTGAAGAAATTCGAGCTTTCAGGAGTTCAAGGCCGTACCCAACCATTGATG 570
 VDGSINPVTVGVVENSSFAGVQGRYPTIDATLI
 GATACTACCAATCTTCCCGCAGAGCCCGCTTCCGAGATCTTCAAGGATTCTTGTGGACTACCTACCTTGGACTCTAGCGTG 665
 DTTNLAEEAAWEILQGFLSLGPLSLDSRVQSKD
 CTTCAGTCTATCGACCGAGAGCTATCGACCCGACTATCGTCTCGATTCTTCAATCATTTTTACGAGCAGAATGAGAGAATTC 760
FSLWTESYGGHYGPAFFNFHFEONERiangs
 TTAATCGTGTTCAGCTTAATTTCACTCTCTCGGAATTAATAACCGCATCATCGAGAGCGGATCCAGGCCCTTACTACCCGT 855
 VNGVQLNFNSLGIINGIIDEAIQAPYYPEFAV
 AACAACTACCTACCGTATCAAGCGTGTCAACGAGACCGTCTACAACATACGAAGTTTCCCAACCAATGCCAAATGGTCCAG 950
 NNTYGIKAVNETVYNYMKFANQMPNGCQDLIS
 CACCTGCAACAGACAAACCCACCCGATTAGCTGACTACGCCCTCTCGCCGAAGCCACCAACATGTCCAGGACAATGTTGA 1045
 TCKQTNRALADYALCAEATNMCRDNVEGPY
 ACCCTTTCTCGTGGTGGTGTGTATGATATTCGGCATCCATATGATGACCCGACTCCGCCAAGTTATTACAACAAATTTCTGG 1140
 YAFAGRGVYDIRHPYDDPTPPSYNKF LAKDS
 GTCATGGACGCTATCGCCGTCAACATCAACTACACCCAGTCCAATATGACGTCTACTACGCTTCCAGCAAACAGCGACTTT 1235
YMDAIGVNINYTQSNNDVYYAFQQTGDFVWPN
 GTTCATCGAAGACCTCGAGGAGATCCTTCTCTCCCGTGGTGTCTCCCTCATCTATGCCGACCCGATTACATCTGCAACTG 1330
FIEDLEEILALPVRVSLIYGDAADYICNWFGG
 AGCCCGTTTCCCTCGCTCGGAATCTCCCAACCCGCCAGTTCCGAAGCCGAGGTACACGCCCTGAAAGTCAACGGCGTGG 1425
 QAVSLAANYSQAAQFRSAGYTPLKVNVEYGE
 ACTCCGAGTATGGTAATTTCTCTTCACTCCGCTCTATGAGCCAGCCCATGAAGTCCCATACTACCAGCCCATCGCTCCCTG 1520
 TREYGNFSFTRVYEAGHEVPYYQPIASLQLFN
 CGCGACTATCTTCGGTGGGATATCGCAGAGCCGAGAGAAGATCTGCCCACTACAAGACGAATGGAACGGCTACAGCTAC 1615
 RTIFGW DIAEGQKKIWPSYKTNGTATATHTQ
 CGTCCGTCCCGCTCCCTACCGCTACCAGCATGTCCAGTGTGGTATG 1668
 SSVPLPTATSMSSVGMA.

Figure 3: DNA sequence and deduced amino acid sequence of *Aspergillus oryzae* strain ATCC 20386 carboxypeptidase I. Amino acids determined by protein sequencing of purified *A. oryzae* ATCC 20386 carboxypeptidase I are underlined. Primer positions used in PCR are indicated by dotted arrows. Predicted signal sequence peptide is double underlined.

		Consensus											
		1020304050											
1	MRGYEFLSVLPLVAASWALPGSTPASVGRRQLPKNP TG VK TLTANNVTI	A.oryzae CPl Penicillium S3 Penicillium SI A.phoenicis A.niger											
1	- - - - - FVK - - - - -												
1	MRITSAIASLLLV - - - - - G T A T S L Q N P H R R A V P A P L T H R S V A S R A V												
1	MLFRSLSTAVLAV - - - - - S L C T D N A S A A K H G R F G Q K A R D A M N I A N G S A N A V												
		Consensus											
		P.V. Y.G.											
51	R - - - - - YK - - - - - E P G A E G V C E E T - - - - -	A.oryzae CPl Penicillium S3 Penicillium SI A.phoenicis A.niger											
1	- - - - - S T K N Y R F L N E K T K A N L V H - - - - - H L												
4	- - - - - - - - - - - - - - - N S G I C E T T - - - - -												
42	- - - - - P V E R R S N D F E Y L T N K K T A R F L V N G T S I												
48	K H S L K I P V E D Y Q F L N N K K T K P Y R V E - - - - - S L												
		Consensus											
		F.F. W.NGGPG.											
		90100110120											
82	- - - - - T F F W F F E A R H N P E T A P I T L W L N G C G R G S D S L I G L F F E E L G P C H - V N S T F D	A.oryzae CPl Penicillium S3 Penicillium SI A.phoenicis A.niger											
43	S R A L F Y I F Q P T I G E P V D E V T I W M N G C G P E C S G M E S F L Q E T G R F L W Q P G T Y A												
29	- - - - - M W F F E A R N N P Q Q A P L A A W F N G C G P E C S S M I G L F Q Q E N G P C H F V N G D S T												
90	S S L F F W F F P S Q N P D A S D E I T I W L N G C G P E C S S L D G L L Q Q E N G P F L W Q P G T Y K												
96	S R S L F F V F Q P T I G E P V D E T T I W L N G C G P E C S S L E A L S P G E C R F V W Q P G T Y Q												
		Consensus											
		N. S W N Q P . G . G . S											
		130140150160170											
129	D Y I N P H S W N E V S N L L F L S O P L L G V G F Y S D T V D G S I N P V T G V V E N S S F A G V	A.oryzae CPl Penicillium S3 Penicillium SI A.phoenicis A.niger Consensus											
93	P V E N P Y S W V V L T N V L W V D O P V G T G C Y S I G T P T A T S Q E E T A - - - - -												
77	P S L E N S W N N Y A N M I Y I D O P I G T G C Y S Y G T - - - - - D D V T S T V T A A P Y V - - - - -												
140	P V P P Y S W T N L T N V V Y I D O P A C T G C F S P G P S T V N D E E D V A - - - - -												
146	P V E N P Y S W V N L T N V L W V D O R V G T G C F S L G V P T A T S E E E I A - - - - -												
		Consensus											
		180190200210220											
179	Q G R Y P T I D A T L I D T T N L A A E A A W E I L Q G T L S G L P S L D S R V Q S K D F S L W T - - - - -	A.oryzae CPl Penicillium S3 Penicillium SI A.phoenicis A.niger											
132	- Q D V K F F K N F Q K T Y G I K N F K I Y V T												
119	- W N L L Q A Y A Q R P E Y E S R - - - - - D F A I F T - - - - -												
179	- A Q N S W F K H F V D T F D L H G R K V Y I T												
185	- E D V K F F K N W Q Q I F G I K N F K I Y V T												

	10	20	30	40	50	
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						
A.oryzae CPl						
Penicillium S3						
Penicillium SL						
A.phoenicis						
A.niger						
Consensus						

ESY.G.Y.P.

Consensus

228
156
142
203
209

A.oryzae CPl
Penicillium S3
Penicillium S1
A.phoenicis
A.niger

230
240
250
260
270
VQLNFNLSLGIINGIIDEAIIQ
ALAYDPCIGQFD-YVQEEIIP
QNVNIVALGVNNGWIDSTIQ
IQINDPSINS-D-SVMMYSP
ALAYDPCIGQFD-YVQEEAP

F...N

Consensus

277

A.oryzae CPl
Penicillium S3
Penicillium S1
A.phoenicis
A.niger

280
290
300
310
APYYPE--G--
VVPFVKENANL
EKAYID--
AVRHLNHYNNI
VVPFVQKNNAL

C

Consensus

320
253
231
299
306

A.oryzae CPl
Penicillium S3
Penicillium S1
A.phoenicis
A.niger

320
330
340
350
360
KQTNRTALAD--YALCAEAT--NM
LFFNYTSMANEDVFDVYNEVFKEINP
SQSGSTSD--CTNAD--SV
AP--EITEDCQVWDVYDI
KAMNWS--PTCDVYDI

Consensus

364
301
270
344
353

A.oryzae CPl
Penicillium S3
Penicillium S1
A.phoenicis
A.niger

370
380
390
400
410
DDPTPPSYYNKFLAKDSVMDAI-GVNI
SLVYQPAAGATVYFDRADVKKALHAPN
NDPYPPKTYSTYLSDDPTVVKAI-GAR
-LGF--GPDNYSFNRSDVQKILHVPP
EVDYLPAPASTLT-ALIKRAMHAPNIT

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:			
COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Denmark	0585/96	20 May 1996	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
		.	<input type="checkbox"/> YES <input type="checkbox"/> NO

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applications)

Attorney's Docket Number.
4990.200-US

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this applications is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

U.S. APPLICATIONS		STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	Patented	Pending	Abandoned
08/726,880	October 4, 1996		x	
08/757,534	November 27, 1996		x	

PCT APPLICATIONS DESIGNATING THE U.S.

APPLICATION NO.	FILING DATE	US SERIAL NUMBERS ASSIGNED (if any)			
PCT/DK97/00230	May 20, 1997			x	

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Steve T. Zelson Elias J. Lambiris Cheryl H. Agris Valeta A. Gregg
Reg. No. 30,335 Reg. No. 33,728 Reg. No. 34,086 Reg. No. 35,127

Send Correspondence to: Steve T. Zelson, Esq.
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, New York 10174-6400

Direct Telephone Calls To:
Steve T. Zelson
(212) 867-0123

1	Full Name of Inventor	Family Name BLINKOVSKY	First Given Name Alexander	Second Given Name
	Residence & Citizenship	City Davis	State or Foreign Country California	Country of Citizenship United States
	Post Office Address	Post Office Address 955 Cranbrook Court	City Davis	State & Zip Code/Country California 95616, USA
2	Full Name of Inventor	Family Name BERKA	First Given Name Randy	Second Given Name
	Residence & Citizenship	City Davis	State or Foreign Country California	Country of Citizenship United States
	Post Office Address	Post Office Address 3609 Modoc	City Davis	State & Zip Code/Country California 95616, USA
3	Full Name of Inventor	Family Name REY	First Given Name Michael	Second Given Name
	Residence & Citizenship	City Davis	State or Foreign Country California	Country of Citizenship United States
	Post Office Address	Post Office Address 605 Robin Place	City Davis	State & Zip Code/Country California 95616, USA
4	Full Name of Inventor	Family Name GOLIGHTLY	First Given Name Elizabeth	Second Given Name
	Residence & Citizenship	City Davis	State or Foreign Country California	Country of Citizenship United States
	Post Office Address	Post Office Address 1880 Cowell Blvd. Apt. 171	City Davis	State & Zip Code/Country California 95616, USA

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applications)

Attorney's Docket Number.
4990.200-US

5	Full Name of Inventor	Family Name KLOTZ	First Given Name Alan	Second Given Name
	Residence & Citizenship	City Dixon	State or Foreign Country California	Country of Citizenship United States
	Post Office Address	Post Office Address 725 Collier Drive	City Dixon	State & Zip Code/Country California 95620, USA
6	Full Name of Inventor	Family Name MATHISEN	First Given Name Thomas	Second Given Name Erik
	Residence & Citizenship	City DK-2100 Copenhagen	State or Foreign Country Denmark	Country of Citizenship Denmark
	Post Office Address	Post Office Address Nordborggade 3, 3.t.h.	City DK-2100 Copenhagen	State & Zip Code/Country Denmark
7	Full Name of Inventor	Family Name DAMEMANN	First Given Name Claus	Second Given Name
	Residence & Citizenship	City DK-2860 Søborg	State or Foreign Country Denmark	Country of Citizenship Denmark
	Post Office Address	Post Office Address Høje Gladsaxe 61, 7. t.h.	City DK-2860 Søborg	State & Zip Code/Country Denmark
8	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
9	Full Name of Inventor	Family Name	First Given Name	Second Given Name
	Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1 <i>Alexander Shinkovskiy</i>	Signature of Inventor 2 <i>Jan Mathisen</i>	Signature of Inventor 3 <i>Thomas Mathisen</i>
Date 10/9/97	Date 10/9/97	Date 10/9/97
Signature of Inventor 4 <i>Ej Salighly</i>	Signature of Inventor 5 <i>Alan N. Klotz</i>	Signature of Inventor 6 <i>Thomas Mathisen</i>
Date 10/9/97	Date 10/9/97	Date Jan. 22 1998
Signature of Inventor 7 <i>Claus Dammann</i>	Signature of Inventor 8	Signature of Inventor 9
Date 26/1 - 1998	Date	Date